SAPA 美中藥協 WASHINGTON D.C

in partnership with

Big Idea CONNECTpreneur

2020 SAPA-DC Biotech Investors Pitch Conference

— A virtual event bridging capital and projects between the US and China

October 17, 2020

8:30 AM - 1:30 PM (EDT)

Event registration: https://sapa2020.eventbrite.com

www.sapadc.org

Conference Agenda

8:30-9:05 AM	**VIRTUAL NETWORKING (via Private Message)** **Event MC: Bei Ma, MS, EC of SAPA-DC** **Founder and CEO, The Pinea Group LLC**
9:05-9:15 AM	**WELCOME and OPENING REMARKS** **Lingquan "Vince" Deng, PhD, President of SAPA-DC**
MORNING KEYNOTE SESSION **Moderator: Lingquan "Vince" Deng, PhD, President of SAPA-DC**	
9:15-9:35 AM	***China Biotech/Life Sciences and Investment Landscape*** **Lawrence Jin, China Life Sciences and Health Care (LSHC) National Audit Leader, Partner of Deloitte**
9:35-9:55 AM	***Personal Perspectives from a Leading VC on Investing in China*** **Yi Shi, PhD, Founding Managing Partner of Lilly Asia Ventures (LAV)**
9:55-10:10 AM	***When Will We See China-Based Global Biotech Companies? An Insider's View*** **Xianping Lu, PhD, Chairman and CEO of Chipscreen Biosciences**
10:10-10:25 AM	***Legend Biotech's China and Global Development Story*** **Frank Fan, MD, PhD, Co-Founder and CSO of Legend Biotech**
BIOTECH PITCH SESSION **Moderator: Tien Wong, Managing General Partner of Opus8 Phoenix Fund,** **Founder & Host of CONNECTpreneur Community**	
10:25-11:25 AM	**Biotech Pitch: 10 promising biotech companies** **Adaptive Phage Therapeutics** **Alphyn Biologics** **AxImmune** **BioFactura Inc.** **BiOneCure Therapeutics** **DEKA BioSciences** **Hopstem Biotechnology** **LinkedUp Bioscience** **Pendrea Pharmaceutical** **VerImmune Inc.**
BIOTECH INVESTORS PANEL SESSION **Session Introducer: James Early, EC of SAPA-DC**	
11:25-12:05 PM CHINABIO®	**Panel Discussion #1 (Co-organized with ChinaBio): Trends and Considerations for Biotech Investors** **Moderator and panelists:** **Dr. Debra Yu, President and CBO, LianBio** **Konstantin Poukalov, Managing Director, Perceptive Advisors** **Dr. Karen Hong, Partner, Novo Ventures** **Dr. Marietta Wu, Managing Director, Quan Capital** **Dr. Jing-Shan "Jennifer" Hu, Senior Advisor, Qiming Venture Partners USA**
COMPANY START-UP PANEL SESSION **Session Introducer: Bei Ma, MS, EC of SAPA-DC**	
12:05-12:45 PM 漢康資本 HANKANG CAPITAL	**Panel Discussion #2 (Sponsored by Hankang Capital): Opportunities and Challenges in Biotech Start-up, Growth and IPO** **Moderator and panelists:** **Dr. Li Feng, Partner, Finnegan**

	Lili Zheng, International Tax Partner, Deputy Managing Partner of Deloitte US Chinese Services Group, Asia Pacific Cross-Border Services Leader **Will Cai, Partner, Cooley LLP** **Dr. John Mumm, Co-founder and CEO, Deka Biosciences**
COMPANY AND SERVICE SHOWCASE SESSION **Moderator: Charles Li, MBA, President-Elect of SAPA-DC**	
12:45-1:30 PM	**COMPANY PRESENTATION & VIRTUAL NETWORKING (via Private Message)** **Hankang Capital, Kevin Yuan, MBA, Founding Managing Partner** **Polaris Strategic Partners, Jane Fang, MD, MS, Founder and CEO** **AAVnerGene, Daozhan Yu, PhD, Founder and CEO** **BioHealth Innovation, Judy Costello, Managing Director of Economic Development**

HOSTS

LINGQUAN “VINCE” DENG, PHD, PRESIDENT OF SAPA-DC

Dr. Lingquan “Vince” Deng works in a NASDAQ-listed biotech company in Maryland and is responsible for a few pre-clinical projects involving 'first-in-class" innovative drugs, with a strong focus on blood diseases. Vince was trained under the supervision of two academicians in Europe and the US, during his PhD and postdoc fellowship, respectively. He has published over twenty peer-reviewed research papers in top-tier journals including Cell and Nature Microbiology and is a well-known young researcher in the field of glycobiology and carbohydrate chemistry. Dr. Deng currently serves as President of the Sino-American Pharmaceutical Professionals Association - Washington DC (SAPA-DC). He conducted his postdoctoral research at the Johns Hopkins University and the University of California, San Diego. He earned his Ph.D. degree from the Royal Institute of Technology, Stockholm, Sweden, and a Bachelor's degree from Tongji University, Shanghai, PRC.

JAMES EARLY, BS, MANAGING PARTNER, TAMARACK ADVISORY

James Early is the managing partner of Tamarack Advisory, which facilitates cross-border investment between the US and China. James has more than 20 years of experience in institutional finance, beginning in the hedge fund industry, and then later as Director of Research and Analysis at The Motley Fool, one of the world's first Internet investment advisory companies; he also served as a Lead Advisor for 10 years and his equity track record in the US and London outperformed both the S&P 500 and FTSE 100 for the entire decade of his tenure. James has served on the advisory boards of private equity funds Blue Ocean Capital and Arcis Capital Partners and is a partner in Shenzhen Oriental Investment. James is a member of the Wall Street Fintech Club and an executive committee of SAPA-DC (the Sino-American Pharmaceutical Association), and Mensa. James often appears as a special guest on CCTV, Phoenix TV, CNN, BBC, CNBC, The Wall Street Journal, and other international media.

CHARLES LI, MS, MBA, VP BUSINESS DEVELOPMENT, CR MEDICON RESEARCH, INC

Charles Li has twenty years of working experience in drug research and development, possessing broad life science expertise including medicinal chemistry, radiochemistry, molecular imaging/diagnostics, protein therapeutics, and cell therapies for cancer and neurodegenerative diseases, from preclinical development to clinical studies. He worked at Peking Union Medical college and National institutes of Health as a research scientist before his career transition into a business development professional after his MBA from Johns Hopkins University. Charles has played a variety of leadership roles in many organizations and has served many biomedical startups, both in US and China. Charles currently leads the US business development of CR Medicon, which is one of the youngest and fastest growing clinical development CRO in the world. Charles is also one of the founding members of SAPA-DC, Executive Council 2018~2020, and the SAPA-DC President-Elect 2019.

HOSTS

BEI MA, FOUNDER AND CEO, THE PINEA GROUP, LLC

Pinea provides cross-border strategic business development, market access, regulatory and clinical services to assist medical device, digital health, IVD, pharma and biopharma organizations delivering patient-centric innovative solutions to the US and international markets. With headquarters in Washington DC metro area, Pinea works with strategic partners with proven business track record located in Europe and Greater China Region. Bei Ma served as Vice President of Global Healthcare Business Development and a key thought leader in Global Healthcare Sector for the British Standards Institution (BSI) Group since 2016. Her broad-based thought leadership spans global business development, global regulatory affairs, global harmonization and standards development, emerging technology and innovation, strategic alliances, and public-private partnerships. From 2008 – 2016, Bei Ma provided scientific and business development expertise in identifying and pursuing new opportunities that support the public health mission and global strategy at the United States Pharmacopeial Convention (USP). Bei serves as Executive Council member at SAPA-DC. She is also Board of Directors at Rockville Economic Development Inc. and Board Member at VisArts Center in Maryland.

TIEN WONG, CEO, OPUS8, INC.; FOUNDER AND HOST, CONNECTPRENEUR COMMUNITY

Tien Wong is a tech entrepreneur and investor. He is CEO of Opus8, Inc. which makes tech investments and helps VC and PE funds, and companies raise capital. Opus8's Phoenix Fund invests in remarkable entrepreneurs who are changing the world through disruptive technologies. Sectors include fintech, health tech, marketing tech/CRM and cyber.

Tien is Chairman of Lumious, a provider of advanced tech training and mobile e-learning solutions to Fortune 500 customers, and is also Chairman of Lore, an IT and BPO services company. Tien was co-founder and CEO of CyberRep, Inc. until its acquisition in 2003 by a "Fortune 500" company. CyberRep was one of the world's largest CRM companies with 2,300+ employees and $80+ million in revenue. Today, the CyberRep business units are divisions of Xerox and Conduent with over $2.5 billion in revenue.

A recognized international expert in CRM, direct marketing, and BPO, Tien has presented at dozens of conferences globally and has been featured on ABC, Fox, NBC, and CNBC, as well as in Time Magazine, The Washington Post, and Inc. Magazine.

In 2001, Tien received the Ernst & Young Entrepreneur of the Year award and was inducted into the EY Entrepreneur of the Year Hall of Fame. He was a Washingtonian magazine "Tech Titan" in 2017, 2018, and 2019 as well as a 2012 and 2013 Washington Business Journal Power 100 selection as one of the regions' s most influential leaders. Tien was appointed by Governor Martin O'Malley to the Maryland Venture Fund Authority which oversees $84 million in VC allocations; he serves on several boards including the Investment Advisory Board of the Commonwealth of Virginia's Center for Innovative Technology GAP Fund. He is a Mentor at the Conscious Venture Lab and Mach37 Cybersecurity accelerators. Tien is an Entrepreneur in Residence at Georgetown University and a graduate of Dartmouth College.

SPEAKERS & PANELISTS

WILL CAI, PARTNER, COOLEY LLP

Will Cai is a corporate partner and the head of Cooley's Asia capital markets practice. He is also the founding partner of CYL & Partners, a firm of Hong Kong solicitors which practices in association with Cooley HK, a Hong Kong registered foreign law firm. He represents issuers and global investment banks in US and Hong Kong capital market transactions. He also advises private equity funds and multinationals in their investments in the Greater China region, as well as Chinese companies in their cross-border M&A activities. Will has worked on over 50 successful IPOs in the US and Hong Kong capital markets in the last decade, with a focus on technology and new economy companies. In addition, Will has represented a significant number of leading new economy companies in their M&A transactions, including a number of landmark deals. The deals he has worked on over the years have garnered a number of rankings and accolades including the "Best IPO of 2017" by FinanceAsia Magazine, "Equity Deal of the Year for 2017" at the IFLR Asia Awards in 2018, the largest technology IPO in Hong Kong in 2017, one of China Business Law Journal's Deals of the Year in both 2016 and 2015 and one of Asian-MENA Counsel magazine's Deals of the Year for 2015.

FRANK FAN, MD, PhD, CSO & CO-FOUNDER, LEGEND BIOTECH

Dr. Frank Fan is Co-Founder of Legend Biotech and currently serves as Chief Scientific Officer of the company. Dr. Fan received his medical degree at Xi'an Jiaoton University in 1993 and worked as a surgical resident in the Kidney Transplantation Centre of the university before he pursued his Ph.D. in applied immunology at Hiroshima University, Japan. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of studying the mechanism of human B cell tolerance. Dr. Fan has published numerous peer-reviewed academic journals, including an original article published in Nature Medicine which lead to a major revision in clinical guidelines of pediatric organ transplantation. Dr. Fan's scientific achievement paved the way to demonstrate that small children can be safely transplanted with ABO blood group mismatched organs and saved many lives of infant patients. Dr. Fan was awarded the "New Key Opinion Leader" award by the Transplantation Society in 2006. Dr. Fan founded Legend Biotech in 2015 and the company has grown into a global leader in cancer immunotherapy in just 5 years. A bispecific BCMA-targeting CAR-T product Dr. Fan invented entered into a global partnership with Janssen to co-develop the global markets. The product received Breakthrough Designation from the FDA and PRIME scheme from the EMA. Dr. Fan is now leading the world's largest cell therapy R&D team and is devoted to inventing more innovative technologies for treating solid tumors and other diseases.

SPEAKERS & PANELISTS

LI FENG, PhD, PARTNER, FINNEGAN

Dr. Li Feng practices patent litigation before U.S. district courts, post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), patent prosecution, opinions and counseling, and due diligence. Her technical experience spans a broad range of technologies, including pharmaceutical, biologics, biotechnology, medical device, chemical, agriculture, nanotechnology, cosmetic, and metallurgy. Li has represented a number of pharmaceutical companies in Abbreviated New Drug Application (ANDA) pre-litigation and litigation. She manages a large pharmaceutical patent portfolio covering multiple clinical drug candidates and has successfully represented companies in PTAB proceedings in the areas of biopharmaceuticals, biotechnology and electronics. Li also frequently speaks on intellectual property topics. Prior to practicing law, Li was engaged in extensive academic and industry research, through which she gained broad knowledge and hands-on experience in a wide range of fields, including drug discovery, pharmaceutical analysis and formulation, antibodies, assay development, medicinal chemistry, protein chemistry, molecular biology, and computer-based molecular modeling.

KAREN HONG, PhD, PARTNER, NOVO VENTURES

Karen Hong is currently a partner at Novo Ventures (US), Inc. Prior to Novo Ventures, Dr. Hong was a Senior Investment Director at Takeda Ventures, Inc. based in Cambridge, MA. Prior to TVI, she was a Partner at ProQuest Investments. She is a Board Director at Cyteir Therapeutics and has served on the Board of Directors of Obsidian Therapeutics, Palleon Pharmaceuticals, Clarus Therapeutics, and Agile Therapeutics. In addition, she represented ProQuest as an observer on the Board of Directors of BioRexis Pharmaceutical Corp. (acquired by Pfizer), Gloucester Pharmaceuticals (acquired by Celgene) and LEAD Therapeutics (acquired by BioMarin), among others. She is also a member of the Joint Steering Committee of the Novo Broad Greenhouse, an early stage drug discovery partnership between Novo Holdings and the Broad Institute. She brings over twenty years of experience in life science investing. Prior to joining ProQuest, Dr. Hong led numerous research projects in the area of mammalian cancer genetics and genomics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research. Dr. Hong earned her Ph.D. in biology from the Massachusetts Institute of Technology and holds a B.S. in chemistry and a B.A. in molecular biology from the University of California at Berkeley, where she graduated with honors and as a member of Phi Beta Kappa.

SPEAKERS & PANELISTS

JING-SHAN "JENNIFER" HU, PhD, SENIOR ADVISOR, QIMING U.S. HEALTHCARE FUND

Dr. Jing-Shan "Jennifer" Hu is Senior Advisor at Qiming Venture Partners USA. She has worked in VC investment on innovative therapeutics in the U.S. since early 2016 with roles including Senior Advisor, Venture Partner, Founding Partner for investment firms, including Qiming Venture Partners U.S. Healthcare Fund I and 3E BioVentures. Her success in investment includes leading a $67M series C1 financing of AMRO, followed by its successful IPO on NASDAQ and acquisition by Eli Lilly with $1.6Bn cash in 10 months. Before joining the VC world, she has worked for over 20 years in partnering/licensing, business development, R&D at three multinational pharmaceutical companies and two biotech companies in the U.S. with various roles, including VP and Head of (External) Innovation Center China at Bayer Healthcare Pharmaceutical, Director of Licensing & External Research at Merck&Co (MSD), Head of Functional Biology at Roche Palo Alto, Program Manager of Pharmacogenomics at Affymetrix, and Scientist of Protein Therapeutics at Human Genome Sciences. Dr. Hu obtained her post-doctoral training at Harvard Medical School, a PhD from University of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and a BS from Peking University.

LAWRENCE JIN, NATIONAL LEADER & MARKET MANAGING PARTNER, LIFE SCIENCES & HEALTH CARE, AUDIT & ASSURANCE, CHINA EASTERN REGION, DELOITTE CHINA

Lawrence Jin has over 24 years of auditing and advisory experience in both China and UK. He founded and currently leads LSHC audit practice in Deloitte China and is also the China Eastern Region Market Managing Partner. He has extensive auditing and advisory experience including managing complex engagements for multinational clients. Lawrence has successfully led a number of high-profile IPOs in Mainland China; Hong Kong and the US capital markets with a particular focus on biotech and CRO sectors. He also leads efforts of conducting financial due diligence for industry-leading clients and advising on their risk management including SOX compliance issues. Lawrence is a founding member of Deloitte Chinese Services Group (CSG) and has previously led the UK CSG group. Lawrence currently serves as Members President (Greater China) and Fellow of Institute of Chartered Accountants in England & Wales (FCA ICAEW). He is also a member of the Chinese Institute of Certified Public Accountants (CICPA).

SPEAKERS & PANELISTS

XIANPING LU, PhD, CHAIRMAN & CEO, CHIPSCREEN BIOSCIENCES

Dr. Xianping Lu returned to China in year 2000 to found Chipscreen Biosciences with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D in Princeton until 2000. He participated in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego in 1994 after his postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at Sanford Burnham Institute. Dr. Lu obtained his Ph.D. and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University. With over 30 years of biomedical research and biotech /pharmaceutical experiences in various responsibilities and therapeutic areas, Dr. Lu is a skilled leader of diverse groups and functions in global operating settings. He has published more than 100 peer-reviewed papers in prestigious journals including Nature, Science and The Lancet. He is the lead inventor of over 100 patented inventions in areas of small molecule therapeutics.

JOHN MUMM, PhD, CO-FOUNDER & CEO, DEKA BIOSCIENCES

Dr. John Mumm is Co-founder and CEO of DEKA BioSciences. After earning his Bachelor's Degree from Menlo College, John received a MS from Stanford University and both a MS and PhD from MD Anderson Cancer Center where he discovered that IL-10 directly activates anti-tumor CD8+ T cells. John conducted post-doctoral work for a year at DNAX Research Institute and became a Scientist at Schering Plough where he developed PEGylated IL-10 (AM0010) as an immunoncology asset. He then founded Targenics, later merged with ARMO BioSciences (briefly a publicly traded company), to clinically develop AM0010 and other immune oncology assets. ARMO BioSciences was acquired by Eli Lilly in 2018 for $1.6B up front deal. As a founder and Senior Director of Technical Operations at ARMO, John led the manufacturing and pre-clinical research teams. John served as the Director of Immunoncology R&D at Medimmune LLC and is the author of 28 peer reviewed manuscripts and 28 granted or pending patents. After reviewing the immunoncology space for two years at MedImmune and developing such diverse projects as innate and T cell agonists, CART and other cell therapy projects as well as novel immunostimulatory antibody drug conjugates, John has most recently founded Deka Biosciences. Deka is the next generation cytokine development company created to solve all of the challenges associated with harnessing the massive potential of cytokine therapy. With the most recent failures of all the T cell agonists, and the development and functional challenges associated with cell therapy programs, it is likely that cytokine combinations coupled with targeting modalities administered in conjunction with precision patient selection will be clear value drivers for the pharmaceutical industry for years to come.

SPEAKERS & PANELISTS

KONSTANTIN POUKALOV, MANAGING DIRECTOR, PERCEPTIVE ADVISORS

Konstantin Poukalov joined Perceptive Advisors in 2019 and is a Managing Director at Perceptive Advisors focused on various strategies across the Perceptive platforms. Mr. Poukalov serves on the boards of directors of Lyra Therapeutics (Nasdaq: LYRA), Landos Biopharma, Inc., and LianBio, which are portfolio companies of Perceptive Advisors. Prior to joining Perceptive, Mr. Poukalov served as Executive Vice President and Chief Financial Officer of Kadmon Holdings (NYSE: KDMN) from 2014 to 2018. From 2012 to 2014, Mr. Poukalov served as Kadmon's Vice President, Strategic Operations. Prior to joining Kadmon, Mr. Poukalov was a member of the healthcare investment banking group at Jefferies LLC from 2009 to 2012, focusing on companies across the life sciences and biotechnology sectors. Prior to Jefferies, Mr. Poukalov was a member of UBS Investment Bank, focusing on the healthcare industry from 2006 to 2009.

YI SHI, PhD, FOUNDER & MANAGING PARTNER, LILLY ASIA VENTURES (LAV)

Dr. Yi Shi is the Founder and Managing Partner of Lilly Asia Ventures (LAV). Prior to founding LAV in 2008, Yi worked at the U.S.-based Eli Lilly and Company in business development licensing and corporate ventures. Yi holds a Ph.D. in Biochemistry and an M.B.A., both from Duke University. He received his Bachelor's degree in Biology from University of Science and Technology of China.

MARIETTA WU, PhD, MANAGING DIRECTOR, QUAN CAPITAL

Dr. Marietta Wu is Managing Director of Quan Capital, a life sciences venture fund with offices in China & US, and deep expertise in cross-border value creation and global investments. She is a founding member of Zai Lab and served as COO and Director of the company prior to Quan Capital. Zai Lab is a NASDAQ listed company widely recognized as a leader in bringing innovative and transformative medicines to China. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry. She was Managing Director at Burrill & Company, leading Burrill's investments and operation in Greater China, focusing on venture capital investing in China and Taiwan related life sciences opportunities. She also served as acting COO of Waterstone, a specialty pharmaceutical company with key operations in China. Dr. Wu is a frequent speaker and author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference. Prior to her focus on healthcare investments and company building, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company. Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business. Dr. Wu serves on the board of Citrine Medicine, Crescendo Biologics, Innoforce, MEDx Translational Medicine and Zidan Medical. She was a board member of Zai Lab Limited (NASDAQ: ZLAB), Kira Pharmaceutical, Jing Medicine Technology, Taiwan Liposome Company (GTSM: 4152), JHL Biotech (TWEM: 6540), and General Biologics Corporation (TWEM: 4117).

SPEAKERS & PANELISTS

DEBRA YU, MD, PRESIDENT & CBO, LIANBIO

Debra Yu is President and CBO of LianBio, a company focused on bringing paradigm shifting medicines to China and other major Asian markets. The company was founded by Perceptive Advisors and is advancing three leading programs in cardiorenal and oncology. Dr. Yu was most recently Managing Director and Head of Cross Border Healthcare Investment Banking at China Renaissance Securities (US). Prior to that, she was Managing Director of Labrador Advisors, where she advised numerous cross-border partnerships and licensing transactions. Earlier, she was VP Strategy at WuxiApptec and helped to architect and co-lead Pfizer's venture capital team and a member of Pfizer's Worldwide Business Development organization. Dr. Yu was a bay area venture investor for several years, serving as General Partner of Delphi Ventures and Managing Director of Bay City Capital. She also held positions at McKinsey & Co. in New York and London. She began her career as an analyst at Morgan Stanley. Dr. Yu received a BA with high honors in Molecular Biology from Princeton University earned an MD from Harvard Medical School. She served as the Mid-Atlantic Regional Chairperson for Bayhelix for several years prior to serving on the Bayhelix Board in 2018-2019. Dr. Yu is also a Governor of the Asian American Alumni Association of Princeton University and an active supporter for the University's Center for Contemporary China.

LILI ZHENG, PARTNER, DELOITTE TAX LLP

Lili is a senior US international tax partner with more than 30 years of experience in the field. She currently serves as the Deloitte's Asia Pacific Cross-Border Services Leader and Deputy Managing Partner of Deloitte US Chinese Services Group. She has substantial experience in cross-border tax planning and is responsible for Deloitte's overall cross-functional services to MNCs investing Asia as well as Chinese & Asian clients investing in the US. Leveraging on her extensive experience in Deloitte offices in San Francisco, Tokyo, Beijing, San Jose and Hong Kong, Lili provides practical and implementable solutions to multinational companies on their cross-border investment structuring, IP planning, JV planning, M&A, entry and exit strategies. She is a trusted advisor with substantial experience in advising PE/VC funds and their portfolio companies in IPO positioning & restructuring to access different capital markets in the US, Hong Kong, Mainland China, and Taiwan. Fluent in Mandarin and Cantonese, she has a deep understanding of the unique considerations of companies from Asia Pacific on their cross-broader greenfield investments in the US and related supply chain impacts in various industries including but not limited to life sciences and healthcare, technology, financial services and manufacturing.

PRESENTING COMPANY EXECUTIVE SUMMARIES

Adaptive Phage Therapeutics
22 Firstfield Road, Suite 125
Gaithersburg MD 20878 USA
www.aphage.com

Point of Contact: Greg Merril, CEO
E-mail: gmerril@aphage.com

Overview: APT is a clinical-stage biotech advancing personalized phage therapy for treatment of antimicrobial resistant (AMR) bacterial infections. APT's **PhageBank™** platform technology has been used in emergency rescues of over 30 critically ill patients for whom antibiotics had failed. These compassionate use cases put APT in the unique position of having multiple proof points of efficacy and safety in humans before recently initiating FDA-approved clinical trials. In addition, APT is one of the few biotechs awarded US government funding to progress a COVID-19 vaccine to Phase 1 human testing.

Market: Addressable U.S. markets for initial AMR clinical indications exceed $1.6 billion.

Problem: Prior antimicrobial treatments have been 'fixed' while pathogens continue to evolve resistance, making AMR infections an enormous problem worldwide, and causing major health (and business model) issues as traditional antibiotics are now in varying stages of obsolescence. As a result, by 2050, AMR infections are expected to become the leading cause of death worldwide.

Solution: APT's PhageBank and related technologies were exclusively licensed to APT from the U.S. military's Biological Defense Research Directorate (BDRD), and leverage an ever-expanding library of phages that collectively provide evergreen broad spectrum and polymicrobial coverage.

PhageBank phage are matched through a proprietary phage susceptibility test (PST) being commercialized with **Mayo Clinic Laboratories** (MCL) on a global scale. PhageBank is positioned to be the first antimicrobial therapy to continually increase in spectrum of coverage over time and therefore does not require revenue suppressing antibiotic stewardship.

PhageBank required technological breakthroughs in several areas including genomics, bacteriophage purification, machine vision, machine learning (artificial intelligence), and years of phage collection by the U.S. Military. APT's in-house manufacturing and phage matching technology has already been leveraged to treat over 30 patients under FDA-approved compassionate use.

Leadership:

Greg Merril – CEO: Founding CEO for 3 prior VC-backed fast growth life-science companies, including Immersion Med (NASDQ: IMMR). A Regional Ernst & Young Entrepreneur of the Year

Carl R. Merril, MD, CAPT USPHS (ret) - Chief Science Officer: NIH Emeritus Scientist with 200+ scientific publications. USPHS Distinguished Service Medal

Michael Brownstein, MD, PhD – Chief Medical Officer: Prior NIH Scientific Director. Prior Director of functional genomics, J. Craig Venter Institute. Co-founded several successful biotech companies

Subhendu Basu PhD – COO: Previous Senior Director and Head of Scientific Affairs, Emergent (NYSE: EBS). Prior faculty at the Center for Vaccine Development, University of Maryland

Robert J. Hopkins, MD - Vice Pres., Clinical Development: 25+ years of regulatory and clinical development experience. Prior FDA, Merck, Emergent, BARDA

Michael King, MBA - Chief Business Officer: Prior CFO / CBO of PDS Bio and Aprecia Pharma, and CBO of Atrin Pharma. Prior US Senior Exec. for Sandoz GmbH, a subsidiary of Novartis AG

Amy Fix, MS, MBA - Head of Regulatory Affairs: Prior Senior Vice President of Regulatory Affairs at Novavax (NYSE: NVAX) and Senior Director of Regulatory Affairs at Emergent (NYSE: EBS)

Michael Orndorff, CMA - Corp Controller: Prior Controller at Emergent (NYSE: EBS). Prior public accounting auditor at Reznick Group (now CohnReznick) and Aronson

Funding to date: $36 million from all sources (2020 revenue est.: $12M from Dept of Def. contracts)

Current Investors: Mayo Clinic, Alexandria Venture Investments, Hackensack Meridian Health Ventures, NYSE-listed Pharma (confidential), TEDCO

Alphyn Biologics Executive Summary

Dermatology Platform: Successfully Treated MRSA Drug Resistant Skin Infections

Multi-Target Therapeutics
A New Class of Drugs
More Powerful Therapies

MANAGEMENT TEAM

Neal Koller – Chairman & CEO
President & CEO, Board of Directors for 6 life science businesses achieving milestones and exit with last exit at 16x; Sr. Exec. Wyeth Pharma

Steven Pentelnik – President
P&G Exec. responsible for $1B early-stage technology portfolio & global manager of $750M Beauty Care Products

Gary Pekoe, PhD - Chief Scientific Officer
Directed multiple biotech product development programs including **FDA approval of Mupirocin**
Founded strategic regulatory / clinical company focused on early stage innovations

Jazmyne Mink - Scientific Researcher
Center Director, Ailie Wellness Center

COMMERCIAL PARTNERS

Eagle Analytic Services - Analytics Laboratory
Emery Biopharma - Microbiology Laboratory
PCCA - Formulation and Manufacture
TagOne - Supply Chain Management
Catalyze - Grant Services
IQVIA - Regulatory and Clinical Trials
Troutman Pepper - IP and Legal
EinserAmper - Finance and Tax

SCIENCE ADVISORS

Prof. Dr. med. Joachim Drevs
Adj Professor, U. Clinic Freiburg, Germany
Director, Unifontis Oncology Clinic, Sickte, Germany

Lawrence Schachner, MD
Chairman Emeritus Dermatology; Director Ped. Dermatology
University of Miami School of Medicine

Jonathan Zenilman, MD
Chief, Infection Diseases Bayview, Professor of Medicine
Johns Hopkins

Patric Lundberg, PhD
Associate Professor, Microbiology/Molecular Cell Biology
Eastern Virginia Medical School

Shekhar Mitra, PhD
Sr VP, Global Innovation, Procter & Gamble (retired)
President, InnoPreneur, LLC

Dennis P. West, PhD
Vincent W. Foglia Family Research Professor of Dermatology, Northwestern U.

Marc Goldberger, MD, MPH
FDA Dir. Office of Antimicrobial Products (retired)
Regulatory Consulting, MG MD MPH LLC

David Hussong, PhD
FDA CDER Microbiology (retired)
CTO, Eagle Analytic Services

Kathrine Laessig, MD
FDA Dpty Div Director, Anti-Infective Products (retired)
VP, Therapeutic Strategy, Drug Development, IQVIA™

FUNDING TO DATE

Founders	$ 870K (excluded from capitalization)
Seed Round	$ 1 million

FINANCING SOUGHT

2 Tranches: $2.5 million now / $ 12.5 million

USE OF PROCEEDS

$ 176,800	Regulatory
$ 1,398,600	Manufacturing, Development
$ 88,100	Business Development
$ 823,900	G&A (IP, acct, legal, personnel, trvl)

COMPANY DESCRIPTION

Alphyn is a dermatology company solving the largest and most serious skin diseases, including infection and drug resistant infection, facing humankind. Alphyn's patent-pending breakthrough AB-101 platform biomaterial treats the root causes of these skin diseases, not just symptoms.

ALPHYN SUMMARY & ACHIEVEMENTS

- AB-101 is a new class of drug due to its unique Multi-Target Therapeutics activity afforded by its multiple bioactive compounds
- Alphyn's 1st product targets Eczema - it is anticipated to replace current eczema treatments that have significant efficacy and side effect failings
- AB-101 is anticipated to be effective resolving infected eczema, including drug resistant infections, as well as effective against multiple other root causes of eczema in one topical treatment
- AB-101 kills *S. aureus* bacteria which is a superantigen or 'super causer' of eczema
  - *S. aureus* causes infection, including MRSA drug resistant infection, itching, inflammation, skin damage
  - AB-101, by killing bacteria including *S. aureus* and MRSA bacteria, treats a key root cause of eczema
- AB-101 is effective at killing dangerous and drug resistant bacteria
  - MRSA and Mupirocin resistant MRSA
  - Multi-drug resistant *Pseudomonas aeruginosa*
  - Multi-drug resistant *Streptococcus pyogenes*
- AB-101 is expected to have a much longer period of efficacy than the antibiotics it replaces
- Unique attributes of Alphyn's topical AB-101
  - Multiple bioactives, versus only 1 bioactive in most standard drugs
  - More effective than standard drugs, including ability to treat infections and eradicate MRSA
  - Demonstrated efficacy at eradicating MRSA in the lab and in initial human use
  - Accelerated path and lower cost to obtain FDA approval
  - Early exit strategy
- Successful FDA Pre-IND meeting, completed
  - FDA agrees that the current topical of choice, Mupirocin, needs replacement
  - FDA has experience with the AB-101 raw material
  - FDA agrees with Alphyn's approval path
    - Ready for Phase 2 trial no later than 2022 at significantly lower cost
- Key commercialization partner network established
  - Leverages world class expertise
  - Minimizes logistics costs
- Supply chain has 50+ years of experience with Alphyn's raw material
  - FDA has approved that supply chain for another drug using the same raw material
- 1st drug product formulations completed and in testing
- 6 patents filed, additional applications in draft, and, additional market protections defined

ALPHYN OPPORTUNITY

- Alphyn is initially targeting the 26.4 million US eczema patient population, valued at $13B
- AB-101 has significant competitive advantages:
  - There are no individual topical therapies that treat all root of causes eczema (infected/non-infected)
  - AB-101 treats multiple eczema root causes:
    - Itching, inflammation and improving skin health
    - AB-101 targets the most significant cause of eczema: MRSA drug resistant infection (reported ~25%)
- Early exit opportunity due to commercial attractiveness
  - Unique MRSA superiority
  - Need for a new 1st line topical treatment
  - AB-101 Multi-Target Therapeutics has a rich and deep skin disease new product pipeline

Contact: Neal Koller +1 (410) 690-8687 or nkoller@alphynbiologics.com

Highlight: Ax-101 is an immuno-oncology drug candidate which stimulates the immune system in multiple ways to fight cancer and has been proven in humans to be safe and effective.

Summary: Ax-101 has been shown to increase good cytokines while decreasing bad cytokines, increasing the M1/M2 macrophage ratio, reducing checkpoint molecules, and has shown a measured increase in immune system lethality and restored delayed type hypersensitivity (DTH) in humans. In animal studies, Ax-101 in combination with immune checkpoint inhibitor drugs has been shown in multiple cancers to increase complete response by 30-40% in colorectal, bladder, and lymphoma and 100% in melanoma. Mean tumor volume was reduced by 32-64% in colorectal, bladder, and lymphoma and 100% in melanoma. Our goal is to return to the clinic in combination with approved Immune Checkpoint Inhibitors such as Keytruda and Opdivo and show significant improvements in CR (complete response) and MTV (mean tumor volume) reduction.

Originally developed as a single agent drug candidate, Ax-101 has been safety tested in both animals and humans, with proven effectiveness resulting in tumor shrinkage and restored immune system function. The mechanisms of enhancing the immune system have been shown to be the same in animals and humans.

MD Anderson and Memorial Sloan Kettering Cancer Center are enthusiastic to host Ax-101 Phase I and II clinical trials.

Market: Immunotherapy has become an important weapon in the treatment of cancer. 2022 worldwide ICI (Immune Checkpoint Inhibitors) market is estimated to reach $25+B Their cure rate is only between 10-20% because cancer shuts down the immune system or hides from it. In many cases, ICI drugs alone have a temporary effect after which the cancer will resume deadly growth. Ax-101 combined with ICI drugs delivers a One-Two Punch, boosting the immune system to kill cancer and may offer a improved patient outcomes.

It is believed that Ax-101 alone activates and strengthens the immune system giving it better chances to fight cancer. As a single agent in human clinical trials, it demonstrated safety and effectiveness (tumor shrinkage, bolstered immune response). Ax-101 in combination with ICI drugs in animal models have shown to be safe and effective against multiple cancers (bladder, colon, melanoma and lymphoma).

Intellectual Property and Strategy: AxImmune has all rights and IP for Ax-101.
Orphan drug status filed and approved for two cancers (metastatic melanoma and multiple myeloma). FDA grants seven years of marketing exclusivity after FDA approval. Intent is to file for many more cancer indications upon FDA approval.
Patent has been filed for combination therapy with Immune Checkpoint Inhibitors (ICI) and Ax-101:

- WO 2018/085698 A1
- PCT/US2017/06005

Capitalization Summary
Ax-101 as a single agent drug has been previously been proven safe and effective in humans.
Funding to date $16M+
Current status: Pre-IND received positive and clear pathway for IND from the FDA
Next Steps and Financing Needed: Raising $25M
Today through IND filing: $2M
Phase I Clinical Trial: $3M
Phase II Clinical Trial: ($20-40M) depending upon number of cancers and CI drugs

Contact Information: Kent A. Murphy, Ph.D., CEO
AxImmune.com
kent@aximmune.com
540-558-8596

BioFactura

Executive Summary

BioFactura, Inc.
8435 Progress Dr Ste Z
Frederick, MD 21701
240-620-3566
www.biofactura.com

Management Team:
Darryl Sampey, Ph.D., President & CEO
Jeffrey Hausfeld, M.D., Chair & CMO

Bank:
M&T Bank

Legal:
Wilson Sonsini/Lacki & Co

Accountant:
JJ Schmelzle & Co.

Funding to Date:
>$14M by licensing, contracts & grants
$1.8M Series A Preferred Stock (closed)
$6.2M Series B Preferred Stock (closed)
$30M Series C Preferred Stock (open)

Mission: BioFactura develops and commercializes high-value biosimilars (*i.e.*, generic biopharmaceuticals) and biodefense medical countermeasures (MCMs) using its patented *StableFast*™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture.

Financing Strategy: BioFactura currently seeks to raise $30M thru the issuance of Series C Preferred Stock to continue advancing a portfolio of two biosimilar drugs through clinical development and scale-up its biopharmaceutical manufacturing processes for late stage trials and commercial launch. As each product achieves preclinical analytical biocomparability and successfully completes a Phase I clinical trial, the Company will proceed to Phase III clinical trials, as needed and with commercial partners depending on product and/or territory. Sales and distribution will begin after final FDA or other regulatory approvals. Since inception, BioFactura has raised over $22 million through licensing, contract, and grant revenues as well as private investment. In 2017 and 2018, BioFactura was cash-flow positive. These funds have allowed the Company to achieve critical product development, capability expansion and commercialization milestones with minimal shareholder dilution. The Company currently holds seven patents for its *StableFast*™ platform with other patents pending and maintains exclusive patent positions with its biodefense assets through licenses with the U.S. Government.

Business Strategy: BioFactura executed its first *StableFast*™ biosimilar platform license in 2013 with Momenta Pharmaceuticals (Cambridge, MA), a global leader in biosimilars commercialization to develop a partner-selected biosimilar. In 2018-20, the Company is advancing three new high-value in-house biosimilar drug candidates to the clinical development stages. Two programs have achieved the preclinical proof-of-concept stage and are ready for manufacturing and clinical development. Reaching the clinical inflection point with each product will make the assets attractive for partnering or further in-house commercialization. This biopharmaceutical product development engine coupled with U.S. Government biodefense funding, such as the recently awarded $67M Smallpox contract, will enable the rapid commercialization of BioFactura's products with revenues exceeding $150M in 4 years and over $1B in less than 10 years.

Competitive Advantages: BioFactura's studies demonstrate that *StableFast*™ provides several key advantages:

- Novel multiplex selection strategy — Higher productivity and stability than single marker approaches
- Cholesterol-free — The ONLY NS0 platform for single-use technology vs the legacy GS-NS0 platform
- Diversity — Broad choice of production cell lines offer precise product quality matching to the brand name
- Regulatory friendly — Commercially-proven NS0 production cell line and serum-free from start to scale-up
- Broad range of biosimilar targets — All NS0 and SP2/0 manufactured brand name products (>$24B)
- Competitive production yields — Proprietary technology enhances volumetric and final production yields

Market: The global biosimilars market is projected to grow from $11.8B in 2020 to $35.7B by 2025 with a Compound Annual Growth Rate of 25% with the (*reportlinker.com, 2020*) with the monoclonal antibody segment growing at the fastest rate during the forecast period. Key drivers of future growth include the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. In addition, the global market seems highly favorable due to increasing pressure felt by countries of all development stages to control the spiraling costs of healthcare and provide access to lifesaving medicines to their populations. BioFactura has targeted an addressable niche in the biosimilars market with current innovator revenues of over $24 billion. These 13 blockbuster drugs such as Stelara (US$6.3B), Simponi (US$3.0B) and Synagis (US$1.1B) are optimally suited for biosimilar development employing the *StableFast*™ technology.

Jeffrey Hausfeld, M.D., Chairman and Chief Medical Officer
jhausfeld@biofactura.com
(301) 792-8601

BioFactura, Inc.
8435 Progress Drive, Suite Z
Frederick MD, 21701

Team: Dr. Darryl Sampey co-founded BioFactura in 2004 and as President and CEO manages all strategic and scientific endeavors of the Company. He has over 20 years industry experience developing biological drugs and holds a B.S. in Chemical Engineering and a Ph.D. in Bioengineering. Retired surgeon Dr. Jeffrey Hausfeld leads BioFactura's Board of Directors and all medical, business development and investor affairs. Since departing the clinic in 2005, Dr. Hausfeld earned an M.B.A. from Johns Hopkins and a degree in organizational development from the George Washington University and has been a successful healthcare entrepreneur for over 15 years.

Platform: BioFactura's patented *StableFast*™ platform is the next-generation NS0-based stable cell line development system that permits rapid generation and cloning of manufacturing cell lines (US Pat 8,076,102; China, Australian, Singapore, Korean and European patents allowed). Our technology improves upon and will displace Lonza's GS-NS0 system, the only commercial platform competitor. BioFactura is targeting marketed biologic drugs for biosimilar development that are currently manufactured in the Lonza NS0 system or in the closely related SP2/0 cell line. This platform is simple to use, fast, and productive. Recent process intensification efforts assure a high yield of over five grams per liter significantly reducing our manufacturing costs. Multiple *StableFast*™ cell lines have been scaled up for the clinical manufacture of biological drugs.

Products: BioFactura's biosimilar portfolio includes ustekinumab (Stelara), golimumab (Simponi) and palivizumab (Synagis) with current combined innovator market of over $9B. The Company plans to enter a phase 1 clinical trial in 2021 for ustekinumab, its highest value product. BioFactura is also developing two biodefense drugs. In 2019, the Company was awarded a U.S. Government contract valued at up to $67.4M for its Smallpox Biodefense Therapeutic. Upon development, Government sales of this product could exceed $1B.

Biosimilar and BioDefense Product Pipeline



Biosimilar and BioDefense Revenue Forecast





Jeffrey Hausfeld, M.D., Chairman and Chief Medical Officer
jhausfeld@biofactura.com
(301) 792-8601

Rev 24-INV (AUG 2020)

BioFactura, Inc.
8435 Progress Drive, Suite Z
Frederick MD, 21701

Contact: baoh@bionecure.com

BiOneCure-Executive Summary

Introduction & Core Team

Round : **A**
Financing Plan: **$ 10 MM**
Use: **BIO-106 IND** and **other products development**

BiOneCure Therapeutics Inc is a biotechnology company committed to develop world-class **innovative antibody-drug conjugates (ADCs)** for the treatment of cancer. The company was **founded in 2016** by industrial veterans.
The management team consists of **Drs. Haifeng Bao, Dingguo Liu, Wei Yuan, Jan Fang, and Helen Zhong**, with **over 90 years** of combined successful new drug development experience.

New ADC Technologies

I. **Novel ADC payloads/warheads** being developed by BiOneCure enable uniform and high drug-to-antibody ratio (DAR) with superior in vivo efficacy and safety.

II. **Bispecific antibody drug conjugates** target 2 tumor-specific antigens simultaneously to enhance therapeutic efficacy and safety. Multiple patents for a novel antibody, payload (TAT) and ADC products have been filed.

Product Pipeline

The current pipeline includes 5 innovative ADC products. The leading product **BIO-106 (anti-Trop-2 ADC)** will be filed for IND and start Phase I clinical trial in 2021.

Through our **innovative payload platforms**, we are able to create various new ADC products to effectively interact with a **wide variety of targets** and treatment of different cancers.

Market & Deals

Total eleven ADC drugs have been approved since year 2000 when the first ADC drug was approved. **Six of the 11 ADC drugs have been approved within 2 years between 2019 and 2020**, indicating the break point of ADC technologies and development concept.

As an anti-Trop-2 ADC, BIO-106 is expected to be ananti-cancer agent effective against a broad range of tumors as Trop-2 is highly over-expressed in **approximately 20 solid tumors**, including tumors types with unmet medical needs such as lung cancer, triple negative breast cancer etc.


NSCLC


TNBC

For comparison, **$1.27 billion** in sales in 2024 are forecast for a similar ADC drug, ***Sacituzumab govitecan***, which just got approved this year for treatment of triple negative breast cancer.

Related Deals: GILEAD Immunomedics **$ 21B** AstraZeneca Daiichi-Sankyo **$ 6B**

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (Diakine™) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a $T_{1/2}$ life extending tissue targeting, non-immunogenic scFv technology.

In parallel, Deka has developed a precision medicine strategy to select patients who will best respond to our therapies.

Deka was founded in 2019 by John Mumm PhD (CEO) and Pavel Khrimian MBA (CBO). John is a serial entrepreneur with 25 years of start-up, research, manufacturing, and immune modulatory therapeutic development experience. Pavel brings 18 years of CRO, supply chain and large biopharma business development expertise to Deka. We are negotiating a term sheet with a Maryland based VC for a $20 million Series A raise to be provided in two tranches and are looking for syndication partners. Proceeds from the first $10 million tranche will be used to take the proposed cancer therapeutic through IND readiness and submission, with the second $10 million tranche to be used for Phase I clinical development.

We have raised $2.5 million in seed funding to generate in vitro and in vivo data packages for our disease specific Diakines™, showing powerful functionality in their respective models. Our three-year plan includes:

1. Preclinical validation of the anti-inflammatory and cancer assets,
    a. Cancer lead molecule: wt IL-2 coupled with a high affinity IL-10 variant targeting EGFR ($DK2^{10}$) - July 2020
    b. IBD lead suppressive cytokine pair IL-4 coupled with a low affinity IL-10 variant, target TBD - ($DK4^{10}$) - September 2020
2. Development of upstream/downstream manufacturing process, analytical method development PK/PD/Toxicology for both molecules to enable IND readiness
3. File an IND to initiate a Phase I clinical trial in RCC

We have reproducibly manufactured small-scale non-GMP lots, developed our downstream process, and initiated analytical method development. We have negotiated a lease with MGM Belward LLC, to rent laboratory and office space as well as and build a cGMP production facility that will enable the efficient development and manufacturing of our molecules to rapidly initiate Phase I clinical trials.

Deka has been granted its first patent with more immediately pending and has filed multiple provisional patent applications for its technology, its use, composition of matter, and precision medicine selection signatures and assays. There are no third-party obligations against any of Deka's intellectual property.

5720 Ogden Rd,
Bethesda, MD 20816

301-256-4776
khrimianp@dekabiosciences.com

Executive summary

Hopstem Bioengineering is a discovery stage company committed in cell replacement therapy for neural injury and neurodegenerative diseases, such as stroke, traumatic brain injury, spinal cord injury, AD, PD, and ALS, etc. In addition to clinical pipelines development, we also provide state-of-art research grade human neural cells and brain organoids products as well as related services.

Hopstem was founded by Dr. Jing Fan, who earned her Ph.D. degree in neurosciences from University of British Columbia, and received her postdoc training at Institute of Cell Engineering, Johns Hopkins University. Dr. Fan has 15 years of experiences in neural toxicology, CNS disease models, including Huntington's disease, Parkinson's disease, and stroke, as well as neural stem cell biology. Core team members of Hopstem include other 3 scientists with strong neuroscience & stem cell background, GMP expert and business managers. Key advisors of Hopstem include Dr. Ted Dawson and Dr. Valina Dawson from JHU, Dr. Yutian Wang from UBC, and Dr. Frank Li, a former AstraZeneca Director of Regulatory Affairs, etc.

Hopstem has established a world-leading neural differentiation platform as well as patented iPSC reprogramming method and GMP manufactory and quality system. We provide a variety of research-grade products, services and human CNS disease models to pharmaceutical companies, biotech and research institutes, including our patented pro-maturation medium and the cutting-edge homogenous 3D brain organoids.

Our leading clinical product, hNPC01, is a human forebrain neural progenitor cell product for stroke and traumatic brain injuries, etc. Preliminary studies in rat and monkey pMCAO stroke models have suggested that majority of those transplanted hNPCs differentiated into functional neural cells and formed significant new connections with the rat neurons in distal regions. We are now preparing for our first IND meeting in the next 12 months. Other clinical pipelines include hNPC02 for ALS and spinal cord injuries, as well as hNPC-EX, which is the exosome product for AD and Autism.

Hopstem has received $5 million funds so far, and another A+ round of $6 million closed in October 2020. Next round of fund raising to prepare more pipelines to clinical stage will start around June 2021. We are always open to investment opportunities and R&D partnerships.

Executive Summary

LinkedUp Bio, pioneered a novel antibody drug discovery engine that is dedicated to developing novel biological therapeutics for diseases that have limited or no successful treatment.
The gamechanger element is that we can scree the entire natural immune repertoire with unprecedented speed and scales and identified hits rapidly and efficiently, thereby greatly increasing the success rate of potential therapeutics for targets that are hard to drug.

AbLink Platform: Screening the entire immune repertoire for more efficient antibody discovery

LInkedUp Bio is using microfluidic device to enable single B cell encapsulation, and subsequently, extract the information of heavy chain and light chain of antibody from tens of millions of B cells and then transferred them into our in-house engineered yeast system. These antibody copies in the yeast cells maintained their natural heavy chaiin and light chain pair, and good biophysical stabilities of the original B cells. Our yeast strain has both display and secretion mode which enables quick chacterization of the potential hits, eliminating the step for mamamlian expression for further hits validation, a typical bottleneck for many single B cell platfrom.

The AbLink Platform is the only platform allowing comprehensive screening of the natural antibody repertoire. This results in at least 100 times more hits than hybridoma and other single B cell platforms. Other benefits include more extensive epitope coverage, more unique and rare sequences & diversity, higher affinity, and functionality. Currently the platform gathered a great deal of interest in industry as we already collaborated with two biopharmas and several others are in the middle of conversation.

LUB-001 : Tackling malignant melanoma and solid tumors

LinkedUp Bio's first target indication is malignant melanoma, one of the deadliest forms of human cancer, due to the high incidence of metastases and drug resistance. Extensive research supports the role of a new target X for malignant melanoma, potentially affecting tumor growth, survival and metastasis. However, due to the limitations of traditional antibody discovery technologies and the complex structure of the target, there have been numerous antibody candidates that showed limited efficacy in inhibition of tumor growth, never matched the high expectation and promise of a breakthrough treatment.

LinkedUp developed a novel antibody clone for this target X and in vitro data demonstrated drastically improvement of the ability of the immune system to attack the tumor cells. LinkedUp Bio's approach can provide a novel promising treatment for many different types of cancer, such as triple negative breast cancer, glioblastoma, hepatocellular carcinoma, and more.

LUB-002: Tackling congenital muscular dystrophy

Alpha Dystrolycanopathy is a clinically and genetically heterogeneous group of muscular dystrophies with the defective matriglycan which links the muscle cells with extracellular matrix . The cause of the defection involved more than 18 genes, and manifested various degree of severity in clinical symptoms. Currently there no effective therapy for this group of diseases. Novel strategies like antisense, AAV gene therapy, enzyme replace can only address one kind gene a time, making a significant commercial challenge. We propose a novel bispecific antibody approach that functions as a surrogate molecular linker to reconnect extracelluar matrix and the muscle cells to ameliorate sarcolemmal fragility, a primary pathology in patients with alpha-dystroglycan- related muscular dystrophies.

We are currently seeking fund to move our program forward and expand our team.

Team:

Greg Li, Co-founder, President
Stephen Gillies, Co-founder, CSO
Tao Wang, Co-founder, Vice President of Antibody Discovery

Jason Lavinder, Cofounder, Advisory Board

Greg Li PhD, LinkedUp Bioscience Inc | 50C Audubon RD, Wakefield, MA 01880

Tel:781-41-3200 Ext 101 | Email: Gli@Linkedupbio.com

Executive Summary

Pendrea Pharmaceuticals offers a profound and novel opportunity as a Phase 2 clinical stage development company dedicated to the treatment of Solid Tumors and Acute Myeloid Leukemia (AML). Pendrea is the only company working with a class of natural compounds in the body, ceramides, which are the central mediators of a natural defense mechanism against neoplasia and cancer progression. Our lead product, Ceraxa, has shown safety and efficacy as a monotherapy in stage 4 Solid Tumor patients who had failed all previous treatments.

No one else has the means to deliver ceramide as solubility limitations and the need for intracellular delivery have prevented its use as a therapeutic. Pendrea's proprietary technology, which embeds ceramide in the outer membrane of a nanoparticle, overcomes these delivery limitations.

Ceraxa's physical properties result in a long half-life in humans (24 hours) allowing significant accumulation within the tumor, while its dual mechanism of action has been demonstrated to be quite unique in that it kills cancer cells while leaving healthy cells unharmed:

- Once in the tumor, Ceraxa kills cancer cells through inhibition of their high energy glycolytic pathway triggering apoptosis. Proteome analysis shows a huge down regulation of pro-cancerous mitogens
- In the tumor microenvironment, Ceraxa changes the phenotype of tumor associated macrophages from M2 to M1, which reverses immunotolerance and reactivates T-cell response giving Ceraxa a second tumor killing mechanism

Ceraxa has been shown to be exceptionally safe in humans because the biochemical target for Ceraxa does not exist in healthy cells.

In addition to the dual mechanism of cytotoxic killing and immune system reactivation, Ceraxa has been shown in a number of studies to significantly restore and enhance the ability of standard chemotherapeutics to kill cancer cells. Patients whose cancers have relapsed while on frontline standard of care therapies need this restoration of effectiveness. it is in this area of combination therapy that our CMO, Dr. Daniel Vlock, a board certified oncologist, has identified that Ceraxa addresses a totally unmet need which could lead to an efficient and rapid regulatory path to approval, especially since Ceraxa appears safe without adding further side effects. In addition, CMC risk is mitigated as cGMP manufacturing is already established, and shelf-life for Ceraxa is greater than 2 years at room temperature.

The science behind Ceraxa is very deep and extensively published in peer reviewed journals, a number of which are listed in Pendrea's Overview presentation. The development of Ceraxa is the life's work of Prof. Mark Kester, a world leader in ceramide research and head of the NanoStar Institute at the University of Virginia, where Pendrea has access to substantial research resources. Pendrea also has access to resources and clinical sites through Scientific Advisory Board members at Memorial Sloan Kettering and the University of Maryland. Ongoing research involves development of next generation forms of Ceraxa that allow encapsulation of chemotherapeutics in the hollow core of the nanoparticle offering the potential for significant expansion of Pendrea's pipeline and its partnering opportunities.

The management team is highly accomplished in pharmaceutical development and creating significant enterprise value. In particular, the CEO has created liquidity opportunities with his last four companies; two M&As and two IPOs, while the CMO has also built and sold a biopharm company. Together, exits achieved by these two executives exceed $1 Billion.

The company seeks to raise $30 million to complete Phase 2A in 4 Solid Tumor indications and AML, and another $25 million to complete Phase IIB in the best Solid Tumor indication from Phase 2A and in AML. The Company expects to be ready to progress to the start of Phase 3 for Solid Tumors and AML at the end of 3 years.

Anti-tumor Immune Redirection (AIR)

An Innovative Therapy that Redirects Pre-existing Immune Memory from Infection or Vaccination to Fight Cancer

VERIMMUNE



Problem: Cancer remains one of the top 5 leading causes of death worldwide, with a high unmet medical need for novel modalities of treatment. Over the recent years, the advent of immune checkpoint inhibitors has provided a new treatment paradigm for immuno-oncology, leading to remarkable clinical benefits in specific subsets of cancer patients. However, such treatments still have relatively limited overall success rates and are associated with significant toxicities. Physicians have difficulties identifying the most effective treatment for a patient and this results in many patients being ineligible and/or not responding to treatment, or even acquiring resistance.

Opportunity: VerImmune's patented Anti-tumor Immune Redirection (AIR) platform alters the patients' solid tumor to flag it to their own pre-existing immunity derived from prior viral infection or vaccination. AIR virus-inspired nanoparticles target viral antigens to tumor cells to mark those cells as virally infected. This signals the pre-existing viral immune memory T cells to target the tumor cells and destroy them. Clinicians can review a patient's health history or vaccination record (together with a possible companion diagnostic) to leverage the AIR product as a novel cancer treatment option. AIR is applicable for the general cancer population, while serving as a customizable targeted immunotherapy.

Value Proposition:

- ***Biomarker Available:*** Physicians can select patients for AIR treatment via health/vaccine history records and companion diagnostic.
- ***Differentiated Approach:*** AIR's differentiated mechanism of action, independent from PD-1/PD-L1 biology, supports the broad application to many cancers either as a monotherapy or in synergy with existing approved treatments.
- ***Tumor Specificity:*** AIR's platform is tumor-specific and has been systemically administered preclinically with no apparent toxicity.
- ***Tumor Type Agnostic:*** AIR has the potential to target any solid tumor, leveraging a variety of pre-existing immune responses within our body from past infection or vaccination.
- ***Robust Intellectual Property:*** strong foundational IP on Composition of Matter and Method of Use, with additional families covering mechanism, synthesis & methods of treatment.

Go-to-Market Strategy: Our *in vitro* and *in vivo* preclinical results validate the AIR mechanism of action as well as the anti-tumor efficacy in immune checkpoint-refractory murine tumor models. Those data have been established with initial seed funding (~$1.5M). VerImmune is initiating Series A to develop our lead product candidate, VERI-101 (CMV-AIR) to an IND to enable the first-in-human clinical studies and to grow the management team. Potential targets for initial clinical indications are immune checkpoint inhibitor-ineligible cancer patients with advanced or metastatic solid tumors.

VerImmune Inc.

Baltimore, MD
Tel: +1-858-775-9805
Contact: Alain.Rolland@verimmune.com
Website: www.verimmune.com
Sector: Immuno-oncology (Therapeutics)

TEAM

Alain Rolland, Pharm.D., Ph.D., Exec Advisor
COO at Emerald Health Pharmaceuticals, formerly President/CEO and co-founder of CHIME BioTherapeutics, EVP/CSO of HUYA Biosciences International, EVP Product Development at Vical.

Joshua Wang, Ph.D., Founder & CSO
Previously Johns Hopkins Assistant Professor. Experienced in scientific venture creation (Flagship Venture Labs).

John Troyer, Ph.D., Co-Founder & COO
Crafted & led 36 successful INDs during his former tenure as VP of Product Development at PharmAthene & ICON.

Roger Pomerantz, M.D., Board Director.
President, CEO and Chairman of ContraFect Inc., formerly CEO of Seres Therapeutics, SVP at Merck & Co. and Global Head of ID for J&J.

Robert Silverman, MBA, Board Director.
Former CEO of mtm laboratories AG., sold to Roche ($270M). Leadership roles at Cytyc and Viacell, Director of NPD Abbott PPD.

Solomon Langermann, PhD., Business Advisor Chief Scientific Officer (CSO) of NextCure. Former CSO and SVP of Research at Amplimmune Inc. (acquired by AstraZeneca for $225M).

Eric Richman, MBA., Business Advisor
Board Chairman of Lab Connect. Previously, Partner at Brace Pharma, President and CEO of PharmAthene and founding team member of MedImmune.

John Schiller, Ph.D., Scientific Collaborator
2017 Lasker DeBakey Clinical Awardee. 2014 National Medal of Technology & Innovation. Distinguished NIH Investigator. Global Key Opinion Leader in Papillomavirus virus-like particles & Immune Redirection

David Masopust, Ph.D., Scientific Advisor
Key Opinion Leader on T-cell memory. Beckman Foundation Young Investigator awardee, American Society of Microbiology ICAAC Young Investigator Awardee, and NIH Director's New Innovator Awardee.

PARTNERS

BIG IDEA CONNECTPRENEUR FORUM

Founded in 2012 and based in Washington, DC, CONNECTpreneur is a global community of over 20,000 founders, entrepreneurs, private investors, angels, VCs, CXOs and business leaders who celebrate innovation and entrepreneurship. The CONNECTpreneur Investor Network consists of 2500 high net worth private investors and family offices that are seeking outstanding investment opportunities in early stage companies and alternative investment funds. The CONNECTpreneur Capital Access Platform (CCAP) is a compliant technology platform whereby companies can source investment capital via our investor network. Learn more at www.connectpreneur.org.

BIOCENTURY

BioCentury helps C-level biotech executives and investors make business-critical decisions by providing independent deep-dive analysis, high-quality data, and business intelligence on a global scale. We report on and dissect trends before others, helping you to better position your company for change and to capitalize on that change before your competition. No matter where you are in the drug development process—from idea to patient—we help you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. For more information, please visit BioCentury.com.

BIOHEALTH INNOVATION

BioHealth Innovation, Inc. (BHI) nonprofit organization focused on accelerating biohealth (therapeutic, diagnostic, medtech, and health IT) commercialization in the BioHealth Capital Region (Maryland, DC and Virginia). BHI's team of expert Entrepreneurs-in-Residence, analysts, and other professional staff support technology commercialization, industry promotion, workforce, and capital raising activities. These include the development of commercialization plans, market research and promotion, non-diluted funding application assistance, and introductions to investors, strategic partners, business advisors, and potential clients. BHI also manages wet lab and office incubator space for early stage companies, provides soft-landing support for international companies, and works with partners to co-host the annual BioHealth Capital Region Forum and an annual biohealth investor partnering conference. For more information about BioHealth Innovation or the 10/20-21/2020 event email: BHI@BioHealthInnovation.org. Register here for the 10/19/2020 BioHealth Capital Region Forum with networking and 58 speakers: https://www.biohealthcapital.com/forum-2020/

JUDY COSTELLO, MANAGING DIRECTOR ECONOMIC DEVELOPMENT, BIOHEALTH INNOVATION, INC

Judy Costello is Managing Director of Economic Development for BioHealth Innovation, Inc. (BHI). Prior to joining BHI, she served as Director of the Maryland Department of Commerce's Office of BioHealth and Life Sciences and as Deputy Director of the department's BioMaryland Center. In these positions, she has worked to grow the biohealth cluster by supporting industry recruitment and retention, commercialization, workforce, non-dilutive and dilutive fundraising, international soft landing, partnership and promotion activities. She previously worked for the Business Alliance organizing venture pitch forums, entrepreneur bootcamps, tech transfer showcases, educational seminars, and other programs connecting entrepreneurs, faculty innovators, students, and industry leaders in Maryland, DC and Virginia with each other and with those providing funding and other resources to young companies. Prior to joining the Business Alliance, Costello held positions in economic development, financial services marketing, and university public relations. She is a graduate of Georgetown University, and holds a MBA from Loyola University in Maryland.

PARTNERS

CHINABIO® GROUP

Since our founding in January 2007, ChinaBio® Group has successfully helped nearly 100 US, European and Asia-Pacific life science companies achieve success in China. Leveraging our consulting and advisory teams' significant experience in China's life science industry, and our extensive proprietary databases, we have helped our clients identify over 1,400 in-/out- licensing and M&A opportunities and raise over $500M in funding in China. Our clients have included many global pharma and life science companies as well as early stage and mid-size companies. ChinaBio® Group is headquartered in Shanghai with offices in San Diego, Silicon Valley, Singapore and Basel, Switzerland

GREG B. SCOTT, FOUNDER & CEO CHINABIO® GROUP

Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on cross-border investment and partnering, including the ChinaBio® Partnering Forum which draws over 1500 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today, a widely read newsletter covering the China life science industry. He also is the current chair for the American Chamber of Commerce Healthcare Committee, and a former board member of BayHelix Group. Greg is considered a leading expert on China's life science industry and is frequently quoted in media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, BioCentury, and other industry publications. Headquartered in Shanghai, ChinaBio® has team members in San Diego, Palo Alto, and Basel, Switzerland.

DELOITTE US CHINESE SERVICES GROUP

As a leading organization serving the most complex global clients, the Deloitte Chinese Services Group (CSG) specializes in responding to unique needs of companies engaged in cross-border investments and business between China and the United States.

Established in 2003, Deloitte's Chinese Services Group (CSG) advises Chinese companies expanding their global presence and multinational companies (MNCs) operating or seeking to operate in China.

We have professionals who speak Chinese and/or understand Chinese business culture in 90 countries and regions within Deloitte Touche Tohmatsu Limited's member firms, with approximately 2,000 bilingual resources in the United States. This dedicated network is committed to providing professional advice and comprehensive solutions to better serve our global clients.

To stay ahead of the curve in putting the needs of clients as our priority, the CSG continues its efforts in evolving and adapting to the changing dynamics of the marketplaces and provides advice and solutions to clients to address their complex business challenges.

SPONSORS

HANKANG CAPITAL

Hankang Capital is a venture capital firm dedicated to investing in the bio-pharmaceutical, diagnostic and medical device industries. The Hankang Capital team manages both RMB and USD funds, and has invested in over 20 biotech companies since 2015, among which InnoCare (09969.HK), Akeso (09926.HK) and Chipscreen (688321.SH) successfully went public in the last couple of years and became front-runners in the China biotech industry.

KEVIN YUAN, MBA, MANAGING PARTNER, HANKANG CAPITAL

As the founder of Hankang Capital, Mr. Yuan is responsible for overall management of the firm and investment decision-making. With nearly 20 years of experience in the biopharmaceutical industry, he has led investments in numerous companies in the pharmaceuticals, medical devices, and diagnostics fields. He has vast connections and resources especially in the China biotech industry. Mr. Yuan now serves on the boards of directors of InnoCare (09969.HK), Conmed, Huahui Health, and Pulmongene. Previous notable investment cases include InnoCare (09969.HK), Akeso (09926.HK), Chipscreen (688321.SH), Abbisko and Eastern Biotech, etc.

Mr. Yuan holds a Master of Business Administration degree from China Europe International Business School.

POLARIS STRATEGIC PARTNERS, INC.

Polaris Strategic Partners is a preeminent provider of clinical trial services for emerging and growing biopharmaceutical companies with global aspirations to conduct clinical development projects in US and China.

Clinical trials are sophisticated research projects performed in a complex business environment. Emerging and growing companies have a limited number of assets at the clinical stage. As a result, you rely on your clinical trials to be meticulously conducted in order to achieve business goals by bringing new and differentiated products to the market. There is no room for error. This unique need can hardly be met by large clinical contract research organizations (CROs) whose operations and business models are geared toward supporting mature companies with large clinical portfolios.

The CRO industry is evolving from large, one-size-fits-all offerings to bespoke, culturally matched services that are more effective. We are leading this change with our unique PolarisConnect platform. Through PolarisConnect, we focus on sourcing best-in-class clinical trial capabilities and designing unparalleled trial execution plan that is unique to support ex-US emerging biopharmaceutical companies to achieve trial success in the US. We provide tailored strategic guidance as well as seamless service execution that is anchored by decades of world-class experience in commercial clinical trial operations and outsourcing. We bring deep therapeutic area expertise with proven track record of managing clinical trial businesses in prestigious biopharmaceutical and rare disease companies.

Polaris Strategic Partners is your partner for better trials. We focus on your needs and operate in a culturally sensitive way. We provide insightful guidance, practical know-how, valuable connections and comprehensive solutions to support you to achieve trial success in the US.

SPONSORS

JANE FANG, MD, FOUNDER & CEO, POLARIS STRATEGIC PARTNERS, INC.

Dr. Jane Fang has 25 years of unique multidisciplinary experience in medical practice, life science research and global biopharmaceutical R&D. Her pharma experience includes clinical trial design, study protocol development, strategic planning, trial operations, outsourcing, vendor selection, study management, patient recruitment, data analytics and monitoring, regulatory standards and submissions. Dr. Fang is also a pioneer in digital innovations for clinical trials from medical devices to virtual trials.

Dr. Fang possesses broad international experience in both US and China with extensive global study experience in oncology, autoimmune and respiratory diseases, metabolic and cardiovascular diseases, infectious diseases, and vaccines. Dr. Fang contributed to AstraZeneca/MedImmune's Durvalumb (Imfinzi), Benralizumab (Fasenra) and FluMist development programs.

Dr. Fang received extensive medical education and fellowship training at one of the most prestigious medical universities in China. She also earned an M.S degree in healthcare management and informatics from University of Pittsburg. Prior to founding Polaris Strategic Partners, she had 20+ years of progressive career at leading global biopharmaceutical companies such as AstraZeneca/MedImmune and Schering-Plough/Merck.

AAVNERGENE

AAVnerGene Inc. is an innovative company developing new technologies to make AAV based gene therapy more accessible and affordable. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening platform has high complexity to find the best AAV for each specific disease therapy, so to increase productivity, efficiency and specificity while decrease manufacture pressure, side effects, immunity and price.

With more than 16 years of AAV gene therapy front line expertise, AAVnerGene provides you cutting edge ideas, designs, high quality AAV packaging, products, library construction and screening services. Collaboration is welcome to promote the advance of the thriving area and bring hopes to patients. Together, we find the cures. Please refer to www.AAVnerGene.com for more information and send your questions to daozhan.yu@aavnergene.com.

DAOZHAN YU, PhD, CEO, AAVNERGENE INC.

Dr. Daozhan Yu graduated at University of Maryland at Baltimore in Molecular Medicine. He had worked on different diseases including Diabetes, Obesity, Cardiovascular disease and Neuronal disease. He developed a new method to generate brown fat cells, which can be used to treat diabetes and obesity. He first generated the iPS cells from Niemann-Pick disease patient and used the differentiated neuronal cells to screen and get two promising treatment drugs, one of which is at Phase III clinical trial. He also develops a first-in-class drug for heart disease, which is at preclinical stage.

In recent years, he has been focusing on gene and cell therapy, especially AAV delivered gene therapy. In 2015, he joined Dr. Weidong Xiao's lab at Temple University and focused on AAV basic research and Hemophilia A gene therapy. Later, he joined Vigene Biosciences and led the virus production and innovation department to deliver thousands of AAV productions for universities and companies from all over the world. The quality and productivity helped the company thrive in the AAV production business.

In 2019, he Co-founded the company, AAVnerGene Inc. AAVnerGene's mission is to develop new vector and process to increase the AAV delivery efficiency and specificity, and thus reduce the side effects and cost, which ultimately dictates the success of AAV gene therapy.

SPONSORS

CR MEDICON

CR Medicon, An Integrated Clinical Development Platform. CR Medicon is a clinical development CRO dedicated to providing high-quality services including regulatory affairs, medical affairs, clinical operation, data management, statistical analysis, programming, pharmacovigilance and biological sample analysis. CR Medicon is one of the most trusted and fastest-growing clinical trial service providers for domestic and overseas sponsors. charle.li@crmedicon.com; 732.624.9052

CHARLES LI, MS, MBA

Charles Li has twenty years of working experience in drug research and development, possessing broad life science expertise including medicinal chemistry, radiochemistry, molecular imaging/diagnostics, protein therapeutics, and cell therapies for cancer and neurodegenerative diseases, from preclinical development to clinical studies. He worked at Peking Union Medical college and National institutes of Health as a research scientist before his career transition into a business development professional after his MBA from Johns Hopkins University. Charles has played a variety of leadership roles in many organizations and has served many biomedical startups, both in US and China. Charles currently leads the US business development of CR Medicon, which is one of the youngest and fastest growing clinical development CRO in the world. Charles is also one of the founding members of SAPA-DC, Executive Council 2018~2020, and the SAPA-DC President-Elect 2019.

ATTENDEES

EVENT HOSTS			
First Name	**Last Name**	**Job Title**	**Company**
Lingquan "Vince"	Deng, PhD	President	SAPA-DC
James	Early, BS	Managing Partner	Tamarack Advisory
Charles	Li, MS, MBA	VP, Business Development	CR Medicon Research, Inc.
Bei	Ma	Founder & CEO	The Pinea Group, LLC
Tien	Wong	CEO	Opus8, Inc.

SPEAKERS & PANELISTS			
First Name	**Last Name**	**Job Title**	**Company**
Will	Cai	Partner	Cooley LLP
Frank	Fan, MD, PhD	CSO & Co-Founder	Legend Biotech
Li	Feng, PhD	Partner	Finnegan
Karen	Hong, PhD	Partner	Novo Ventures
Jing-Shan "Jennifer"	Hu, PhD	Senior Advisor	Qiming U.S. Healthcare Fund
Lawrence	Jin	National Leader & Market Managing Partner	Life Sciences & Health Care, Audit & Assurance, Deloitte China
Xianping	Lu, PhD	Chairman & CEO	ChipscreenBiosciences
John	Mumm, PhD	Co-Founder & CEO	DEKA BioSciences
Konstantin	Poukalov	Managing Director	Perceptive Advisors
Yi	Shi, PhD	Founder & Managing Partner	Lilly Asia Ventures
Marietta	Wu, PhD	Managing Director	Quan Capital
Debra	Yu, MD	President & CBO	LianBio
Lili	Zheng	Partner	Deloitte Tax LLP

PARTNERS			
First Name	**Last Name**	**Job Title**	**Company**
Jerry	Chen	Intern	Big Idea CONNECTpreneur Forum
Kim	Gordon	Marketing Manager	BioCentury
Judy	Costello	Managing Director Economic Development	BioHealth Innovation
Greg	Scott	Founder & CEO	ChinaBio

PRESENTING COMPANIES			
First Name	**Last Name**	**Job Title**	**Company**
Greg	Merril	CEO	Adaptive Phage Therapeutics
Neal	Koller	Chairman & CEO	Alphyn Biologics
Kent	Murphy, PhD	CEO	AxImmune
Jeffrey N.	Hausfeld MD, MBA, FACS	Chairman & Chief Medical Officer	BioFactura Inc.
Haihong (Helen)	Zhong	VP of Pharmacology	BiOneCure Therapeutics
John	Mumm, PhD	President & CEO	DEKA Biosciences
Jing	Fan	Founder & CEO	Hopstem Biotechnology
Greg	Li, PhD	President	LinkedUp Bioscience
Chris	Prior, PhD	CEO & Chairman	Pendrea Pharmaceutical
Joshua	Wang	Co-Founder & CSO	VerImmune, Inc.

SPONSORS			
First Name	**Last Name**	**Job Title**	**Company**
Sunny Yun	Lai	Senior Business Program Specialist	Deloitte
Yincheng	Zhang	Partner	HanKang Capital
Jane	Fang	Founder & CEO	Polaris Strategic Partners, Inc.
Daozhan	Yu	CEO	AAVnerGene
Charles	Li	VP, Business Development	CR Medicon Research, Inc.

ATTENDEES			
First Name	**Last Name**	**Job Title**	**Company**
Fredric	Abramson	Founder & CEO	Golden Thread Technology, Inc.
Michael	Adler	Managing Partner	Law Office of Michael E. Adler
Sean	Adler	CEO	GZI
Ali	Afshar	Post-Doctoral Fellow	JHU
Maria Gracia	Agurto Osorio	CEO	SCerise
Ray	Ahn	Investment Manager	DAYLI Partners
Ron	Ainsworth	Principal	Boustead & Co
Abiola	Akala	Principal	Abiola Incorporated

ATTENDEES			
First Name	Last Name	Job Title	Company
Luis	Alvarez	CEO	Theradaptive, Inc.
Berkan	Ates	Investor	Rutherford Global Investments
Lingbin	Bai	BD Director	Shinko Pharm
Haifeng	Bao	CEO	Bionecure Therapeutics
Jiang	Bao	VP of CMC	Bionecure Therapeutics
Subhendu	Basu	COO	Adaptive Phage Therapeutics
Laura	Beldin	SVP	BOA
Khadija	Benlhassan	Director	KB Healthcare
Chris	Bennett	Founder & Attorney	Technology-Innovation-Law
Sameer	Bhalesha	CEO	Malvex
Ashley	Bi	AM	HKSTP
Bobby	Bi	Global BD Director	Innovent Biologics
Xiping	Bi	Director	BayRay
Nan	Bing	CEO	D2M Biotherpeutics Inc
Jaime	Boggio	Attorney - IP Law	Brandia LLC - Intellectual Property & Business Law
Hanya Efje	Boulnois	MEDTECH Engineer Student	Hkust
Ross	Breckenridge	CEO	ARJUNA Therapeutics
Brian	Brown	Principal	Big Law Business Development
Judy	Cai	CFO	Segway
Lain	Cai	Director	CRM
Will	Cai	Partner	Cooley
Kathie	Callahan Brady	CEO	Fitci
John	Canter	CEO	KnickleKick
Youfang	Cao	Senior Scientist	Merck & Co.
Zhengkang	Cao	Regulatory Affair	Humphries Pharmaceutical Consulting
Carlo	Caputi	COO, Founder	Hi Hello Coupon
Jason	Cardinal	CEO	Accurome Health, Inc.
Sue	Carr	President	CarrTech LLC
Charles	Cathlin	CEO	TruGenomix Inc.
Difeng	Cen	Partner	Geneunion
Adrian	Chan	Student	Harvard
James	Chan	MGR	Energy
Joseph	Chan	Research Assistant	New York University
Eric	Chang	Executive Director	Kaitai Capital
George	Chang	Chair, Biomed/Biotech SIG	ASQ509
Nannan	Chang	Executive Director	Kaitai Capital
Ernesto	Chanona	Senior Manager	Maryland Department of Commerce
Shailesh	Chavan	Sr Medical Director	Takeda Pharma
Xing	Che	Research Scientist	YDS Medicine, Inc.
Candice	Chen	Investment Analyst	
Dake	Chen	Postdoc	UC Berkeley
Denise	Chen	Partner	GIG
Dong	Chen	Scientist	Yale University
Donghai	Chen	Business Development Director	Protheragen Inc.
JC	Chen	GM	Rabome
Jessica	Chen	PhD candidate	Weill Cornell
Jessie	Chen	VP Product & Application Development	ACROBiosystems
JJ	Chen	Senior Scientist	AstraZeneca
Joan	Chen		Columbia University
Junxian	Chen	Master Student in Public Health	Columbia University, Public Health
Katherine	Chen	Management Consultant	Accenture
Long	Chen	Research Fellow	NIH
Ocean	Chen	BD Manager	Topwin Pharma
Peter	Chen	CEO	BioAI International Inc
Qing	Chen	Director	Merck
Ruby	Chen	Business Development Consultant	UCSF Health
Rui	Chen	Postdoc	Duke
Shan	Chen	President	CubeTech Global Assets
Sumin	Chen	General Partner	Opus8 Phoenix Fund
Sunny	Chen	Senior Director	SparcBio
Veronica	Chen	Director	Merck
Xiaodong	Chen	EVP	SAPA
Yingwei	Chen	Principal Scientist	Potomac Affinity Proteins

ATTENDEES			
First Name	Last Name	Job Title	Company
Yiou	Chen	BD Manager	Topwin Pharma
Yiwen	Chen	Assistant Professor	UT MD Anderson Cancer Center
Zhaomin	Chen	Investment Senior Manager	Boehringer Ingelheim Venture Fund
Haipeng	Cheng	Senior Investment Director	Sangel Capital
Rong	Cheng	Consultant	ZS
Xi	Cheng	DS	Federal Contractor
Yuan	Cheng	General Manager	Cytoheal
Il Hyeong	Cheong	General Manager	CKD
Denise	Cho	Partner	GIG
Chris	Chow	Sales Manager	Hong Kong Biotechnology Organization
Leo	Chow	VP	GF Investment
Brian	Christie	CEO	Brainsy, Inc.
Ann	Chu	Retired Physician	
Jeffrey	Cohen	CEO	MyLifeID
Robert	Colorina	Director	AIAC Group
Dan	Conley	Investor	Healthcare
John	Conner	Chief Operations Officer	Deka Biosciences Inc.
Samantha	Conner	Vice President of Program Management	Deka Biosciences Inc.
Alicia	Coronado	Senior Analyst	LMI
David	Cragin	Director	Merck & Co
George	Cruise	Sci	UY
Xingfu	Cu	Senior Scientist	Entrada TX
Chuanlong	Cui	Graduate Student	Rutgers
Yan	Dai	Senior Investigator	BMS
Jiang	Danli	RA Manager	Canton Biotech Limited Company
Jeff	Davidson	COO	Pendrea Pharma
Stephen	Day	CEO	Day Capital Partners, Inc
Tahmina	Day	COO	Day Capital Partners, Inc
Catherine	De Peuter	CEO	
Rocio	Delgado	MBA Candidate 2021	Johns Hopkins, Carey Business School
Gian	Dell Antonio	Business Development Manager	YAFO Capital (Shanghai) Co. Ltd
Bin	Deng	Senior Scientist	Eisai US Inc
David	Deng	Director, Business Development	Frontage Lab
Mi	Deng	Assistant Professor	UT Southwestern Medical Center
Ulyana	Desiderio	Director, BioHealth and Life Sciences	Maryland Department of Commerce
Taylor	Devine	Founder & Managing Partner	The CDI Group
Yasir	Diab	Patent Examiner	USPTO
Talabiou	Diallo	Student	GWU
Sophia	Diao	Clinical Consultant	Datarevive
Camilla	Dias	Owner	Digital Affinity
Jienyu	Ding	Postdoc	NCI
Jinlong	Ding	Product Specialist	Thermo Fisher Scientific
Wen	Ding	Postdoctoral Associate	Yale University
Yi	Ding	Investment Manager	Sungent Bioventure
Bob	Dinkel	Director	RE Dinkel LLC
Tuochuan	Dong	Principal Biostatistician	Novartis
Lisa	Dorsey	Managing Partner	Innovative Capital Access
Xiaowei	Dou	Manager	Harvard Medical School
Yueheng	Dou	Engineer	Ethicon
Shouming	Du	CEO	Brainxell
Jimmy	Duan	Scientist	Sify
Peng	Duan	Principal Consultant	Parexel
Greg	Dube	VP	HbO2 Therapeutics LLC
Craig	Elias	Entrepreneur-in-Residence	Bow Valley College
Frank	Fan	CSO	Legend Biotech
Junbao	Fan	Project Scientist	UCSD
Qiyin	Fang	CEO	McFocal Bioimaging
Ray	Fang	Director	Fronthera
Rick	Fang	CSO	CombiAI
Xi	Fang	Founding Partner	Button Capital
Li	Feng	Partner	Finnegan
Lora	Feng	CEO	LFI Solutions
Snow	Feng	Consultant	BCIC

ATTENDEES			
First Name	**Last Name**	**Job Title**	**Company**
Xue	Feng	CEO	Carina Medical
Robert	Fine	Editor	Cool Blue Media
Brian	Ford	International Finance Manager	Kybora
Hangfei	Fu	Relationship Manager	Bank of America
Mao	Fu	Scientist	AAVnerGene Inc
Shao	Fu	VP	Novelstar Pharmaceuticals Inc.
Shean	Fu	Scientists	Takeda
Winston	Fu	Ad	Takeda
Xuebin	Fu	Reserach Associate	Lurie Hospital
Chenchao	Gao	Clinical	Seattle Genetics
Di	Gao	MBA Student	Kellogg
Iris	Gao	Student	WCM
Ronghui	Gao	GM	G-Med Consulting
Ru	Gao		
Xiaobin	Gao	Analyst	MW
Yi	Gao	Senior Director, Regulatory Projects	Humphries Pharmaceutical Consulting
Yinghong	Gao	VP BD & Associate Business Partner	Viva BioInnovator
Yvonne	Gao	Manager	Shanghai FDZJ Bio-Pharmaceutical Co.
Yang	Ge	PhD Candidate	University of British Columbia
Mark	Gilbert	Financial Advisor	UBS
Anton	Gladki	Partner	Design by Monia
Jarrod	Goldsmith	Founder	Entrepreneur Social Advantage Experience
Douglas	Goldstein	SVP Business Development	Alphyn Biologics
Yuying	Gosser	Research Assistant Professor	The City College of CUNY
Zhiqiang	Gou	Ed	ETP Ventures
Richard	Greene	President	RGA Venture Funding & Advisory
John	Gregg	CEO	Balinbac Therapeutics, Inc.
Sergey	Grigorev	Founder	BioAngels
Adam	Grill	CEO & Group President	Odyssey Group
Dennis	Gross	CEO	Pennsylvania Drug Discovery Institute
Liyang	Gu	Senior Associate	Hillhouse
Minjie	Gu	CEO	American Regenerative Medicine
Melissa	Guan	Senior Consultant	Deloitte
Changan	Guo	Scientist	CrisprTX
Dahai	Guo	CEO	Zennova Pharma Group
Dan	Guo	Senior Account Manager	WuXi Advanced Therapies
Jiacong	Guo	Vice President	Biotrack Capital
Morgan	Guo	IPM	Innovate Calgary
Shuling	Guo	VP	Ionis
Xueqi	Guo	Investment Analyst	Fosun Group
Iryna	Halubkova	Senior Impact Investing Manager	TAF
Brian	Han	Deputy Director	KIC
Eileen	Han	VEO Director	GSK
Henry	Han	BD Head	Epicentrx
Henry	Han	Partner	MyBioGate
Lu	Han	VC	Lumira Ventures
Patrick	Han	Principal Scientist	LinkedUp Biosciences
Rachel	Hao	Technical Account Manager	Sino Bio
Wenshan	Hao	CEO	Neomics Pharmaceuticals
Edgar	Harrell	Co-Founder & Partner	Harrell Capital Partners LLC
Bing	He	Postdoc Associate	Florida State University
Estella	He	Senior Investment Advisor	Business Finland
Hao	He	Consultant	Ipsos
Jiangang	He	Regulatory Project Assistant	BLA Regulatory
Juan	He	Vice President, Pharmacometrics	BioPharma Services Inc.
Ran	He	Partner	THC Lawyers
Zhiyong	He	Research Fellow	Monash University
Alexandria	Healing	PM	Aurora Capital
Keith	Herman	Founder	IPA Equities
Jennifer	Hi	Senior Advisor	Qiming U.S. Healthcare Fund
Mi Jeong	Hibbitts	President	Robert & William, LLC
Laura	Hill	Partner	Phoenix Fund
Chaz	Hinzman	PhD Candidate	Georgetown University

ATTENDEES			
First Name	Last Name	Job Title	Company
Fanny	Ho	Member (Retired)	Government of Hong Kong Central Policy Unit
Fei	Hong	Director	Beloteca
Karen	Hong	Partner	Novo Ventures
Laura	Hong	President	KLUS Pharma
Nanfang	Hong	Graduate Student	University at Buffalo
Nancy	Horiye		
Marc	Hrovatic	COO & CFO	Axon Connected
Jung-Ting	Hsieh	MBA Graduate	
Daniel	Hu	BD/Investment Director	Laurel Venture Capital Ltd
Jennifer	Hu	Senior Advisor	Qiming Venture Partners USA
Jin	Hu	Program Director	Guangzhou International Exchange
Johny	Hu	Research Assistant	Peking Uqniversity
Shuai	Hu	Fellow	FDA
Yang	Hu	Assistant Professor	Stanford University
Zhiyuan	Hu	MD	Sino Pharm-CICC
Weiwei	Hua	Director	HPC
Chloe	Huang	Asset Management Analyst	TradeMaster Securities
Hao	Huang	Research Analyst	Haitong Securities
Harris	Huang	Director of Business Development	Zhendong Biopharma International
Larry	Huang	President	Ark Pharm, Inc.
Lisa	Huang	Director	BGI
Lisi	Huang	Head of International BD&L	Shenzhen Foncoo Pharmaceutical Co Ltd
May	Huang	Senior Manager	Taiho Oncology
Mingzi	Hussey	Regulatory Consultant	Zi-medical
Tony	Hussey	Principal Consultant	Zimedical
Patrick	Hylton	Global Marketing Director, China	Amgen
Melody	Ing	Investment Officer	BEMCO
Gary	J	CEO	SYG
Abhishek	Jain	CEO	Verve Logic
Abhishek	Jain	CIO	Devtorium
Vikram	Jha	Founder & CEO	Pucho Life Sciences Inc.
Qingyong	Ji	Group Leader	EMD Serono
Shidong	Jia		Predicine, Inc.
Weitao	Jia	Senior Scientist	Genentech
Mali	Jiamg	Research Scientist	JHU
Alan	Jiang	CSO	XtalPi Inc.
Andy	Jiang	Manager	Wehub Merchant Solution Inc
Bowen	Jiang	Scientist	
Charlene	Jiang	Scientist of Bioscience	AstraZeneca
Ge	Jiang	Vice President	ShanghaiTech University
Joanna	Jiang	Attorney	Ballard Spahr
Joanne	Jiang	CEO	ReINNO Capital
Lili	Jiang	Business Manager	Mybiogate Inc.
Maggie	Jiang	Board Member	The Family Center
Qun	Jiang	Staff Scientist	NIH
Seamus	Jiang	MD	PwC
Sean	Jiang	CEO	YAFO Capital (Shanghai) Co. Ltd
Wenlei	Jiang	Senior Science Advisor	US
Zhen	Jiang	Associate Professor	Boston University School of Medicine
Feng	Jiawu	COO	Hopstem Biotechnology
Claire	Jin	VP	JP Morgan Chase
Lawrence	Jin	Partner	Deloitte China
Shan	Jin	Associate Director	Ziopharm
Zhendong	Jin	Founder, CEO & CSO	InnoBioPharma, LLC
Tim	K	Analysts	Transnew
Kathy	Kang	Associate	Creacion Ventures
Paul	Kang	President	Alta Companies
Vikram	Kansra	CEO	Vicero
Michael	Kao	Chairman	TAiwan ITRI New Venture Association
Ashok	Kapur	CEO	Hawkeye MedTech, Inc
Bin	Karg	Partner	VCL Law LLP
Chirag	Kariya	BD	BB
Doug	Karr	Principal	Values Proposition

ATTENDEES			
First Name	Last Name	Job Title	Company
Mark	Kester	Chief Technical Officer	Pendrea Pharmaceuticals
Ijaz	Khan	Angel	Instatin
Mohd	Khan	Associate & Healthcare Subject Matter Expert	Booz Allen Hamilton
Alexander	Khorokhorin	Managing Partner	Angelico Ventures
Pavel	Khrimian	Co-Founder & CBO	Deka Biosciences, Inc
Richard	Kim	Chief Medical Officer	ImStem Biotechnology
Jay	Kline	Student	Georgetown University
Ted	Koblick	Director of Business Development	Computer Pros On Call
Jodi	Kohut	Researcher	
Prakash	Kolli	CEO	Blue Point Materials Research
Kathy	Kou	Student	Johns Hopkins University
Tim	Kou	Analyst	Transnew
David	Kratochvil	Managing Partner	Vista Capital Advisors, LLC
Max	Kryzhanovskiy	President	MOS Creative
Gao	Kui	AS	Proximavc
Michael	Kull	Chief Narrative Officer	StoryCraft
Sathish	Kumar	Partner	SBSS & Associates
W	L	Professor	Luc
Larry	Lai	Partner	Keytone Ventures
Norman	Lai	CTO	Ibex Bioscience
Sunny	Lai	Senior Business Program Specialist	Deloitte
Vijay	Lakshman	CEO	Brilliant Entertainment, Inc.
Patrick	Lam	Distinguished Professor	Blumberg
Tian	Lang	Student	UPenn
Nadav	Lankin	CEO	Efficacy Care R&D Ltd
Lizzie	Lau	Fellow	HMS
Stanley	Lau	Director	TaiLai Biosciences
Cindy	Law	BD Manager	Kexing Biopharm
Janet	Lawrence	Founder	Harmony Surgical Services
Emily	Le	Founder	Bioinsider
Ines	LeBow	CEO & Founder	Enterprise Transformation Solutions
J	Lee	Student	
Won	Lee	CEO	Idience
Steven	Lehat	Principal	Regulatory World
Ada	Li		
Alex	Li	Managing Director	TF Capital
Cai	Li	Principal Scientist	Merck
Charles	Li	VP	CR Medicon
Charles	Li	Founder	Spring Pharmaceuticals
Dan	Li	Researcher	Wuxi Apptec
Feng	Li	CEO	Beijing Mab-Works Biotech, Inc
Gracey	Li	CEO	Grace Culture
Haishan	Li	Principal Scientist	Perkinelmer inc.
Icy	Li	Managing Director	MSQ Ventures
Jerry	Li	Scientist	Perkin Elmer
Jie	Li	Student	UMD
Jie	Li	Scientist	Tongji University
Jolee	Li	Partner	Lang Sheng Investment
Li	Li	CFO	C F
Lina	Li	CEO	CBI
Louise	LI	Director	ManGo Associates
Luke	Li	Partner	Ampleplus Fund
Mingchao	Li	Investor	Amphora
Peng Peng	Li		
Qing	Li	Principal Scientist	Hansoh Bio
Shaoyong	Li	Scientist	Voyager Therapeutics
Sharon	Li	Managing Director	CHG
Stella	Li	Analyst	Prime Healthcare
Tianyu	Li	Senior Associate	North Beta Capital
Tony	Li	General Manager	Baheal USA
Xiang	Li	Senior Principal Scientist	Poseida Therapeutics
Xiangming	Li	Expert Scientist	GSK Vaccines
Xinxin	Li	VP	MyBioGate 美柏医健

ATTENDEES			
First Name	Last Name	Job Title	Company
Yingjian	LI	Senior Formulation Scientist	Vanda Pharmaceuticals Inc
You	Li	Senior Scientist	Remegen Biopharma
Zhiyuan	Li	Principle Investigator	Keya Bito LLC
Zhuyun	Li	Associate	Bioventure
Xiangming	Li Wang	Expert Scientist	GSK Vaccines
Siga	Liang	CEO	Eagle Heights International
Tao	Liang	Scientist	Alexion
Victor	Liang	Consultant	Guidehouse
Zhibin	Liang	BD Manager	Baheal
Fankia	Lin	Professor	Bit
Li	Lin	Medical Director	Convalife, Co LTD
Lin	Lin	Scientist	PRGN
Lin	Lin	Faculty	BIDMC
William	Lin	VP	SCE Partners
Yanchun	Lin	Graduate Student	WashU
Yoyo	Lin		
Zhengwei	Lin	Technology Licensing Manager	City of Hope
Angen	Liu	Manager	GSK
Chao	Liu	Director, Applied Innovation	BeiGene
Christina	Liu	Technician	Tianjin Biomore Technology
Danny	Liu	Senior Partner	Raid Capital
Dawei	Liu	Associate	WSGR
Dingguo	Liu	VP of Chemistry	Bionecure Therapeutics
Dong	Liu		
Doris	Liu	Research Assistant	UBC
Ellen	Liu	Dr	Clinic
Fang	Liu	Partner	VCL Law LLP
Feng	Liu	Statistical Science Director	Astrazeneca
Jing	Liu	Graduate Student	CAS
Jintan	Liu	Senior Scientist	Merck
Jun	Liu	Scientist	FDA
Karen	Liu	Partner	3E Bioventures
Ming	Liu	Senior Strategic Accounts Manager	Shanghai Mingtian Biological Co.
Patrick	Liu	Rotating CEO	Genscript Biotech
Renpeng	Liu	Scientist	Biogen
Tonny	Liu	Consultant	Bioeaglelab LLC
W. Jerry	Liu	Partner	Fox Rothschild LLP
Weiyi	Liu	Scientist	AstraZeneca
Xiaodong	Liu	President	BioData International
Xiaomeng	Liu	Analyst	Haoyue Capital
Xiaonao	Liu	CEO	Nanobiofab
Xinyu	Liu	Statistician	RG
Yan	Liu	Vice President	BeiGene
Yang	Liu	Investment Manager	Yantai YETDA Biopark
Yang	Liu	Consultant	
Hanson	Lo	Director	Huahai Investment
Loon-Tzian	Lo	Partner	Lomier Holdings, LLC
Cody	Locke	Chief Innovation Officer	Center for Advancing Innovation
Orlando	Lopez	Program Director	NIH
Serhiy	Loshak	IT	Pixellabo SRO
Bowen	Lu	Founder	Arch.bio
Jack	Lu	President & CSO	Hongkang Rentai Pharmaceutical
Jasmine	Lu	Senior Specialist	Shimadzu
Jay	Lu	Scientist	Penn
Jet	Lu	Advisor	Digital Transformation
Lisa	Lu	RA	
Livia	Lu	BD	Synbio Technologies
Louise	Lu		JPM
Lucy	Lu	CFO	Kintor Pharma
Shan	Lu	Regulatory Specialist	BD
Xianping	Lu	Founder & CEO	Chipscreen BioSciences
Zhen	Lu	BD	Sanhome
Thomas	Luan	CEO	Stealth

ATTENDEES			
First Name	Last Name	Job Title	Company
Tom	Lui	Director	Antex
Cheng	Luo	Director Project Development	Sanhome
Daniel	Luo	Investment Associate	Duke
Fujun	Luo	Professor	Bioland Laboratory
Xiaobing	Luo	Senior Scientist	Cellular Biomedicine Group
Yonghua	Luo	Senior Scentist	Klus Pharma
Zhelin	Luo	PM	Merck
Zhongwen	Luo	PhD	UVA
Buyong	Ma	Founder	Molcell Biodesign Inc.
Rui	Ma	Principal	Frees Fund
Ruiyuan	Ma	Consultant	ClearView Healthcare Partners
Shizhong	Ma	Project Director	Shenzhen Salubris Pharmaceuticals
Sophie	Ma	Dr	Clinic
Tianlin	Ma	Founder	BioPegasus, LLC
Xiaotang	Ma	Scientist	Frontage
Xin	Ma	VP, BD	Freelancer
Yanling	Ma	Senior Investigator	
Haiwen	Mackleer	VP Branch Manager	Cathay Bank
Phillip	Madanire	Founder	Acrius
Tai	Mai	Investor	Kluz Ventures
Greyson	Mann		
Victor	Manske	Electronics Hardware Design Engineer	VPM Labs, Inc.
Ymelda Agatha	Manurung		
Shiwei	Mao	Associate	Langsheng Investment
Lee	Mark	Analyst	Windigitalchina
Jose Diaz-Rio	Martinez-Esparza	Principal	Eaton Square
Hannah	Mason	Global Manager, Business Development	Inteleos
Jay	McCrensky	CEO	Marketshare
Don	Megrath	Managing Director	VectorPoint Ventures
Chuchu	Mei	Medical Affair Analyst	Innovent Biologics
Robert	Mendralla	Chief Commercial Officer	RM Enterprises
Fantao	Meng	R&D Director	HbO2 Therapeutics LLC
Phyllis	Meng	CEO	PureVision AI INC
Greg	Merril	CEO	Adaptive Phage Therapeutics
Carla	Merritt	Sr Business Development Rep	Maryland Department of Commerce
Siyu	Miao	Associate	Kaitai Capital
Alina	Miller	Consultant	MillerConsulting
Anthony	Millin	Partner - Chair NEXT	Shulman Rogers
Brian	Morse	Job	Comp
Humphrey	Mu	Vice President	Hollyhigh Capital
Peter	Mu	CEO	TeamedOn
Ying	Mu	CEO	EagleImmune
Charles	Nahabedian	CEO	VideoKall
Devy	Nainggolan	Analyst	Manulife
Doug	Nguyen	Founder	HUSTLR
Jianyi	Nie	Marketing	NuProbe
Bill	Niland	CEO	NeoProgen
Nicole	Niu	Executive Director	Crown Bioscience
Tao	Niu	Manager	Pfizer
Mike	OGrady	CEO	StellaPop
Felicia	Ogunsola	Student	Georgetown University
Bill	Oldham	Chairman	Thought Leadership & Innovation Found.
Kay	Olmstead	CEO & Co-Founder	Nano PharmaSolutions, Inc.
Michael	Orndorff	Corporate Controller	Adaptive Phage Therapeutics, Inc.
Frank	Ouyang	Associate	IDG Capital
Hakan	Ozsancak	Executive Vice President	Self
Pan	Pan	Associate Director of Business Dev.	KLUS Pharma
Weidong	Pan	Director, Business Development	Raybow USA, Inc.
Yanze	Pan	Business Manager	YETDA BioPark
Yidong	Pan	Business Analyst	Starr Insurance Companies
Yuting	Pan	Process Development Associate	Jecho
Kunal	Parikh	Founder	Global Institute for Vision Equity
George	Pearce	Business Development Manager	Moscar Capital

ATTENDEES			
First Name	**Last Name**	**Job Title**	**Company**
Kushtrim	Peci	President	Fonero LLC
Xiaofeng	Peng	Self-Employed	
Madhusudan	Peshwa	Chief Technology Officer	MANA Therapeutics, Inc.
Aprile	Pilon	CEO & CSO	Trove Therapeutics, Inc.
Zach	Pogue	Strategic Advisor	TrueAlgae
Christopher	Pondoc	Business Development Associate	CarrTech LLC
Sathibalan	Ponniah	CEO	Immune Analytics LLC
Mary	Potter	Director	Healthcare Angels
Konstantin	Poukalov	Executive Chairman	LianBio
Chris	Prior	CEO & Chairman	Pendrea Pharmaceuticals
Daniel	Pyne	MD	Haitong
Dongfei	Qi	Scientist	Catalent
Jiahua	Qian	Consultant	Self Employed
Qi	Qian	Associate	Quan Capital
Shenyu	Qian	Business Analyst	Baheal USA
Dorothy	Qin	Financial Consultant	TD Ameritrade
Linda	Qin	PM	Share Capital
Qiang	Qin	Senior Director	Novartis Gene Therapies
Xiaofa	Qin	Founder	GI Biopharma Inc
Ping	Quan	Global Medical Director	Takeda
Bruce	R	Physician Executive	3Sherpas
Harsha	Rajasimha	CEO	Jeeva Informatics Solutions Inc
Yang	Ran	Outreach Liaison	CMU
Roopa	Rangaswamy	Director	QuicqAnalytics & Advisory Solutions
Joe	Reddix	President & CEO	The Reddix Group, LLC
Allyson	Redpath	Director, Entrepreneurship	Maryland Department of Commerce
Huilan	Ren	Associate Scientist	Verve
Li	Ren	Director	BMS
Catherine	Rhee	Consultant	
Morgan	Richards	Student	McMaster University
Phil	Robertson	Principal	BDM Collective
Eric	Rong	President	Sungen
Vikram	S	AI	FusionX
Roozbeh	Sadeghian	Assistant Professor	Harrisburg University
Teemu	Salmela	CTO	WebSafe
Niranjan	Sardesai	Co-Founder, President & CEO	Geneos Therapeutics
Claire	Sha	Partner	AriMed Advisors Ltd
Wendy	Shao	Investment	Bio-Techne
Fang	Shen	Associate scientific Director	Janssen R&D
Hao	Shen	Consultant	Bayer
Nan	Shen	Vice President	Keytone Ventures
Richard	Shen	Managing Director	Sedgwick Yard
Yiqin	Shen	Senior Reporter	MergerMarket
Wanliang	Shi	RA	Johns Hopkins University
Yi	Shi	Founding Managing Partner	Lilly Asia Ventures
ZD	Shi	Research	Gene & Cell Therapy
Cindy	Shu	Director	TF Capital
Sujata	Singh	Associate of Strategic Partnership	KiwiTech
Ranjan	Sinha	CEO	Digbi Health
Lashonsmith	Smith		LaShon
Charles	Song	Associate	Leerink
CJ	Song	Director	GTP, UPenn
Hua	Song	Senior Specialist	Pfizer
Z	Song	Industry Researcher	SZ
Paul	Sorkin	CEO	Perfect Balance Investments
JJ	Sowers	CIO	Sowers Family Office
Dr	Spencer	Chief Investment Advisor	TuT-GA
Robert	Spertell	Investment Banker	Boustead Securities
Aru	Srivastava	Director	SmartAnalyst India Pvt Ltd.
Chaido	Stathopoulou	Postdoc Fellow	NIH
Serena	Stewart		
Jie	Su	Engineer	ShanghaiTech University
Marc	Su	Principal Scientist	Pfizer

ATTENDEES			
First Name	Last Name	Job Title	Company
Sue	Su	Director	Pharma Ltd
Wayne	Su	Director	Xcenda
Yan	Su	CEO	Compass Bioventures
Molly	Sullivan	Student	Georgetown University
Eric	Sun	International BD Director	Nhwa Pharma
John	Sun	Global Program Lead	Novartis
Mingming	Sun	Vice Director	HEC Pharm
Ruby	Sun	VP	NanoTech Pharma Inc
Wei	Sun	Senior Investment Manager	Tianfeng Capital
Ximei	Sun	Associate	MSA capital
Yishan	Sun	Principal Scientist	Novartis
Paulina	Szyzdek	Investor	VC
Aksaraphak	T	Owner	Real Estate Business
Anna	Tai	Senior Principal Scientist	Merck (retired)
Diane	Tai	Chairperson	Allies Building Community Inc
Carol	Tang	Program Management	Ascentage
Jun	Tang	Member	BioKatalyst
Mark	Tang	Managing Director	Good Health Capital New York
Pearl	Tang	Partner	Excel Partners
Sally	Tang	Director of Business Development	Medicilon
Shannon	Tang	Research Scientist	Johns Hopkins University
Tao	Tang	Director	Pachelbel Healthcare
Xin	Tao	Senior associate	Hogan Lovells US LLP
Emma	Tello	Consultant & Founder	Tello IP Services
Bert	Thomas	Sr. VP, Business Development	Bio-Thera Solutions, Ltd.
Samuel	Thomas	Investor	Rebel One Ventures
Li	Tian	Investigator	Tencent
Yu	Tian	Product Manager	Shanghai Mingtian Biological Co.
Yu	Tian	Postdoc	University of Chicago
Irene	Tong	CEO	Reliome
Jessie	Tong	Venture Capital Manager	Santen Pharmaceutical
Mabel	Tong	Director of Corporate Innovation	Aves Lair
Derek	Tou	Founder	SAMA
Thong	Tran	Project Developer	Sati
Jason	Truong	Consultant	Independent
Eric	Tsai	Director of Business Development	Triastek
Shirley	Tseng	SE	Tseng
Madhvi	Upender	CSO & Co-Founder	Awarables
Berna	Uygur	Technology Transfer Fellow	NCI
Joy	van Oranje	Founder	AntiSTROKE
Katya	Vert	CEO	Nostopharma
Princess	Viray	Principal	Boustead Securities
Chunhua	Wan	Senior Data Modeler	Dynamic System Solutions Inc
Adam	Wang	PM	IQVIA
Bonnie	Wang	Executive Director	Viva BioInnovator investment
C	Wang	Physician	AZ
Chen	Wang	Scientist	Sarepta Therapeutics
Chenchen	Wang	Director	Huangzhen Investment Co.
Cheng	Wang	Director	Cowin VC Venture
David	Wang	Partner	Advan Partners
David	Wang	Senior Acceleration Manager	Cincinnati Children's Hospital
Dong	Wang	Co-Founder, President & COO	Enrich Therapeutics Inc.
Eric	Wang	VP	Boston Laboratories
Frank	Wang	VP	Shanghai Medicilon Inc
Fuyuan	Wang	ORISE Fellow	US FDA
Harry	Wang	Co-CEO	Sinldo Infotech Inc.
Hui	Wang	BD	SAPA-GP
Jianfeng	Wang	Director	Premier Financial Alliance
Jin	Wang	Excutive Director	BeiGene
Jing	Wang	Director of BD	IDMO Co.
Karen	Wang	Director	Stout Risius Ross
Kelly	Wang	PM	Ribo
Lili	Wang	Associate Director	Rubius

ATTENDEES			
First Name	Last Name	Job Title	Company
Lillian	Wang	Secretary General	TINVA
Lin	Wang		Jade Biopharma
Mengxiao	Wang	Consultant	International Organization
Monica	Wang	Principal Tech Lead	Takeda
Peng	Wang	Scientist	Lonza
Ping	Wang	Professor	University of Pennsylvania
Qizhao	Wang	CTO	AAVnerGene Inc
Renfei	Wang	Scientific Liaison Manager	Huya Bioscience International
Ruofan	Wang	Scientist	Vigene
Sha	Wang	Founder	Terra Magnum
Sharon	Wang	Researcher	Georgetown U
Sheena	Wang	Chemist	FDA
Shuyu	Wang	Investment Manager	Beijing Tong Ren Tang Chinese Medicine
Simon	Wang	Analyst	Brain.AI
Sophia	Wang	Owner	Bloomwealth
Susan	Wang	SVP Global BD	Asieris Pharmaceuticals
Susie	Wang	Scientist	Inzen Therapeutics
William	Wang	CEO	Bionet Consulting Corp
William	Wang	Researcher	University of Montreal
Xiaofang	Wang	CTO & VP	Imstem Biotechnology, Inc.
Xiaowen	Wang	Scientist	Merck & Co. Inc
Xuya	Wang	Research Investigator II	Bristol Myers Squibb
Yao	Wang	Marketing Director	OBiO
Yaohui	Wang	Senior Biologist	NIH
Yaping	Wang	Reviewer	FDA
Yimeng	Wang	CEO	ReVacc
Yuli	Wang	Researcher 1	WuXi Apptec
Yung	Wang	SVP	Huya Bioscience International
Yunping	Wang	Director	Hitsec
Meykel	Waworuntu	Founder	Venturi
Arnold	Webster	CEO	CRISP LLC
Alex	Wei	Manager	Bright-Gene
Benjamin	Wei	Senior VP Bioanalytical Sciences	Joinn Laboratories
Hongye	Wei	Associate	WG Group
Hongye	Wei	ANA	WHS
Jun	Wei	Bioinformatics	Northshore
Mike	Wen	Director	Transcenta
Yanzhao	Wen	Business Development	China Medical City
Xiaoli	Weng	Tech Transfer Fellow	NIH
Susanne	Wilke	President & CEO	Cognoptix
Anthony	Williams	Managing Partner	Capital4urBusiness, LLC
Liz	Witte	Account Executive	Justworks
Chuanliu	Wu	Professor	Xiamen University
Danny	Wu	Executive Director	Simcere
Guosheng	Wu	VP	Pharmaron
Hao	Wu	Investor	7G BioVentures
Hong	Wu	Self Employed	
Jeffrey	Wu	VP Strategic Partnering & BD	Convalife (Shanghai) Co., Ltd.
Jon	Wu	VP	Xnergy Financial
Julie	Wu	VP	Etern Bio
Lin	Wu	Postdoc	NYU School of Medicine
Marcie	Wu	CEO	Eduwise LLC
Marietta	Wu	Managing Director	Quan Capital
Peter	Wu	Heath Sanitarian	Health Department
Qunfeng	Wu	Senior Scientist	WuXi Advanced Therapies
Xian	Wu	BD Director	Lynk Pharma
Yao	Wu	Vice President	K2VC
Zhijian	Wu	VP	PTC Therapeutics
Lily	Xia	Biomedical Researcher	NIH
Yi	Xia	Self Employeed	
Jay	Xiao	BD Director	Kexing Biopharma Co. Ltd.
Sheng	Xiao	Scientist	Celsius Tx
Jing	Xie	Associate Director	AstraZeneca

ATTENDEES			
First Name	Last Name	Job Title	Company
Kevin	Xie	MD	Admark
Owen	Xie	VP	HH
Weiliang	Xie	Microbiologiest	Duke University
DY	Xing		
Guoqiang	Xing	CEO	Lotus Biotech.com
Julia	Xing	CEO	XPrecision
Sphinx	Xiong	VP	3w Fund
Cong	Xu		LAV
Fuhua	Xu	Principal Scientist	NJII
Jing	Xu	VP OD R&D	Cugene Inc
John	Xu	SVP	Abpro
Lanlan	Xu	SSRA	CMS
Li	Xu	CEO	Li Xu International
Liang	Xu	Partner	Hogan Lovells International LLP, Beijing
Paul	Xu	President	Excellgen
Ran	Xu	Project Manager Regulatory Affairs	Humphries Pharmaceutical Consulting
Randy	Xu	PI	PoxImmunomics
Robinson	Xu	CTO	Beijing Dataharbor Co LTD
Rosa	Xu	Investment Manager	RongSheng investment company
Sylvia	Xu	Director	CMS
Ted	Xu	Chief Rep.	CTTQ
Wenjie	Xu	Senior Investment Manager	MyBiogate
Xiaoping	Xu	Postdoc	NIH
Rui	Xue	Student	Georgetown University
Stephen	Xue	Partner	Huntzest Investment Management
Xiaojiao	Xue	Senior Scientist	PTC Therapeutics
Christopher	Yaen	Associate	Arent Fox
Albert	Yam	Director	Convoy Healthcare
Anna	Yan	Student	Northeastern University
Jas	Yan	Associate	LYFE
Linxuan	Yan	Law Clerk	U.S. District Court District of NJ
Ning	Yan	Director	Consulting Pharmaceuticals
Stephen	Yan	Investment Manager	Fosun Pharma
Yan	Yan	AD	CRISPR Therapeutics
Gary	Yang	BD Manager	WuXi Biologics
Guangyao	Yang	BD Manager	WuXi Biologics
Jake	Yang	Professor	Soochow University
Jerry	Yang	Senior Associate	Citic
Jun	Yang	Executive Director	WuXi Biologics
Liu	Yang	Investment Manager	Kexing Biopharm
Mingtang	Yang	Sr. Manager New Product Launch Excellence	Shanghai Roche Pharmaceutical Ltd.
Zhiyong	Yang	CEO	FZata, Inc.
John	Yao	CEO	Hermay Labs Corporation
Qi	Yao	Research Associate	Moderna
Carolyn	Yarina	CEO & Co-Founder	Sisu Global
Toshikazu	Yazawa	Director	City of Yokohama Rep. to the Americas
Aijun	Ye	Statistician	
Hanqing	Ye	Founder	Beyond Biotech, LLC
Hong	Ye	Scientist	Rapa
Hong	Ye		WPP
Jason	Ye	Director	PwC
Miya	Ye	Partner	MJ Consulting LLC
Tao	Ye	BD Director	Medicilon
Li	Yi	Investor	ZhenFund
Kai	Ying	Scientist	Cumc
Yongcheng	Ying	Investment Director	Yuanbio Ventures
Chen	Yiwen	VP	Zensun (Shanghai) Sci & Tech Co.
Fei	You	Senior Scientist	AstraZeneca
Jerry	Young	Senior Associate	Citic Capital
Daozhan	Yu	CEO	AAVnerGene Inc
Debra	Yu	President & CBO	LianBio
Echiny	Yu	BD Manger	Zenlong
Gary	Yu	GM	Liepin North America

ATTENDEES			
First Name	Last Name	Job Title	Company
Jing	Yu	Manager	GSK
Johnny	Yu	Managing Director	Deloitte
Raymond	Yu	Director	Omni Holdings Group
Xiaozhen	Yu	Associate	Cooley LLP
Adam	Yuan	CEO	Acon Pharma
Dongfen	Yuan	Scientist	Parexel International
Wei	Yuan	COO	Bionecure Therapeutics
Baohua	Yue	VP	Humanwell
Jack	Yue	Associate Director Nanoformulation	Bostal Drug Delivery
Shjyi	Yue	Consultant	Zhiyaomeng
Sajung	Yun	CEO	Predictiv
Theo	Zacharis	Innovation & Strategy Advisor	bioGLOT Ventures
Dewan	Zeng	Executive Director	BeiGene
Jay	Zeng	Physician	Boehringer-Ingelheim
Harry	Zhan	Investment Manager	Button
Jason	Zhan	CTO & VP	Voko
Le	Zhan	Executive Director	Yunion Healthcare Ventures
Le	Zhan	Executive Director	Linked Health Fund
Alena	Zhang	Clinical Data Scientist	FDA
Annie	Zhang	Scientist	TT
Bingcheng	Zhang	Intern	Yunfeng Capital
Cheng	Zhang		
Chenxi	Zhang	Senior Analyst	Haoyue Capital
Cuiting	Zhang	PhD Student	University of Macua
Dan	Zhang	CSO	ClinChoice
Ellen	Zhang	BD Manager	Biocytogen
Eric	Zhang	VP	dMed pharmaceutical
Han	Zhang	Business Development Manager	Shenzhen Foncoo Pharmaceutical
Hazel	Zhang	Associate	
James	Zhang	CEO	Phoenix DX Ltd
Jane	Zhang	BD Director	Tecoland Corp.
Jing	Zhang	PV Scientists	Astrazeneca
John	Zhang	VP for Regulatory Affaires	Frontier Biotechnologies, Inc.
Joyce	Zhang	Project Manager	MSQ ventures
Linghua Harris	Zhang	Head, R&D	NanoBiotec LLC
Mengru	Zhang	Communications & Operations Specialist	Guangzhou Int'l Exchange & Cooperation Cntr
Miaomin	Zhang	Associate Professor	Jilin University
Michael	Zhang	Regulatory Lead	DR
Michelle	Zhang	Senior Director & Head of US	PPC
Morgan	Zhang	CEO	USA Elixiria Biotech Inc
Ning	Zhang	CEO	TopEdit Author Services
Peng	Zhang	Formulation Scientist	Pii
Sean	Zhang	VP	Lilly Asia Ventures
Shengjun	Zhang	VP in Clinical	Pharmaron
Taylor	Zhang	Director	BMS
Wei	Zhang	Student	UMD
Xinyun	Zhang	BD Manager	Taimeng Pharm
Xu	Zhang	Scientist	National Cancer Inst.
Yan	Zhang	Investment Director	Dalton Venture
Yan	Zhang	Consultant	Luban Science
Yi	Zhang	Senior Director	Adlai Nortye USA
Yincheng	Zhang	Partner	Hankang Capital
Yongrong	Zhang	Research Associate	University of Maryland at Baltimore
Yoyo	Zhang	Manager	Biomore Inc
Anya	Zhao	Consultant	CGL
Edward	Zhao	Managing Director	Synergen Lab Inc
Guohua	Zhao	Principal Scientist	Bristol Myers Squibb
Haisheng	Zhao	Postdoctoral	GU
Min	Zhao	CSO	CBD Asia
Nanding	Zhao	Deputy GM	Hefei Oborgen Biopharma
Ruby	Zhao	Managing Consultant	ManGo Associates
Yan	Zhao	Senior Manager	PwC
Yanan	Zhao	Partner	Magnet Venture

ATTENDEES			
First Name	**Last Name**	**Job Title**	**Company**
Yuan	Zhao	Senior scientist	Biogen
Jing	Zhen	Senior Scientist	Viela Bio
Julia	Zhen	Director, Innovation Partnerships	Thermo Fisher Scientific
Cixuang	Zheng	Senior Scientist	Sanofi
Lili	Zheng	Partner	Deloitte Tax LLP
Linghua	Zheng	Associate Research Scientist	Yale University
Qiaoyun	Zheng	Postdoctoral Fellow	NIH
Shelley	Zheng	Student	University of Exeter
Ying	Zheng	Bioinformatician	NIH
Zhipeng	Zheng	PhD student	University of Pennsylvania
Elaine	Zhi	Finance Director	Ascentage Pharma
Haihong	Zhong	VP	Bionecure Therapeutics
Chelsea	Zhou	Scientist	John's Hopkins
Di	Zhou	Senior Scientist	Amgen
Gang	Zhou	Head of Medichem	Rafael
Harry	Zhou	CEO	Proviva Therapeutics, Inc
Jerry	Zhou	Founder & CEO	Akeso Therapeutics Inc
Joseph	Zhou	Postdoc	University of Pennsylvania
Monica	Zhou	Investment Manager	Lifespan
Rik	Zhou	Senior BD Director	Fosun Pharma
Shiyun	Zhou	Student	Georgetown University
Ying	Zhou	Senior Scientist	Teva Pharmaceuticals
Charles	Zhu	General Manager	Yinzi Biosciences, Inc.
Guangshuo	Zhu	CEO	United Heath Investments
Jeffrey	Zhu	Investment Analysis Director	Fosun Pharma
Jin	Zhu	Attorney	Fox Rothschild, LLC
Jun	Zhu	CEO	Mokobio Biotech R&D Center
Pei	Zhu	Research Scientist	Creatv MicroTech
Qingsong	Zhu	COO	Insilico Medicine US Inc
Mike	Zou	Precision Medicine	Novartis
Wei	Zou	Manager	Liminal

Deloitte.

Prepare for tomorrow's healthcare ecosystem

The sky is the limit

Deloitte's Life Sciences and Health Care (LSHC) professionals understand the complexity of today's global industry challenges, and provide clients with integrated, comprehensive services anywhere that they do business. Navigating China's fast-growing LSHC market, considering US market entry, and/or joint ventures can be challenging. Our Chinese Services Group, a network of bilingual professionals working alongside our LSHC industry experts, can make all the difference.

Learn more: www.deloitte.com/us/health
Contact: uscsg@deloitte.com

漢康資本
HANKANG CAPITAL

Hankang Capital is a venture capital firm dedicated to investing in the bio-pharmaceutical, diagnostic and medical device industries. The Hankang Capital team manages both RMB and USD funds, and has invested in over 20 biotech companies since 2015, among which InnoCare (09969.HK), Akeso (09926.HK) and Chipscreen (688321.SH) successfully went public in the last couple of years and became front-runners in the China biotech industry.

Representative portfolio companies

INNOCARE 诺诚健华
康诺亚 Conmed Biosciences Inc
Abbisko 和誉
Huahui Health
东方百泰 EASTERN BIOTECH
CureGene 上海柯君医药科技有限公司 Shanghai CureGene Pharmaceutical Co., Ltd.
BESTUDY 上海百试达医药科技有限公司
微芯生物 CHIPSCREEN
Akesobio
TL
尚健生物 SUMGEN
力品药业 LP PHARMACEUTICALS

We are constantly looking for quality projects

Send business plan to: BP@hankangcapital.com

We are constantly looking for best talents

Send CV to: HR@hankangcapital.com

漢康資本
HANKANG CAPITAL

Polaris Strategic Partners is a preeminent provider of clinical trial services for emerging and growing biopharmaceutical companies with global aspirations to conduct clinical development projects in US and China.

Clinical trials are sophisticated research projects performed in a complex business environment. Emerging and growing companies have a limited number of assets at the clinical stage. As a result, you rely on your clinical trials to be meticulously conducted in order to achieve business goals by bringing new and differentiated products to the market. There is no room for error. This unique need can hardly be met by large clinical contract research organizations (CROs) whose operations and business models are geared toward supporting mature companies with large clinical portfolios.

The CRO industry is evolving from large, one-size-fits-all offerings to bespoke, culturally matched services that are more effective. We are leading this change with our unique **PolarisConnect** platform. Through **PolarisConnect**, we focus on sourcing best-in-class clinical trial capabilities and designing unparalleled trial execution plan that is unique to support ex-US emerging biopharmaceutical companies to achieve trial success in the US. We provide tailored strategic guidance as well as seamless service execution that is anchored by decades of world-class experience in commercial clinical trial operations and outsourcing. We bring deep therapeutic area expertise with proven track record of managing clinical trial businesses in prestigious biopharmaceutical and rare disease companies.

Our service suite includes:

- Project management
- Vendor selection and management
- Study planning and start-up
- Project team training
- Proactive site engagement and management
- Study feasibility and site selection
- Patient recruitment and retention
- Site initiation and regulatory submission
- Clinical trial monitoring
- Data management and risk monitoring
- Clinical sample management
- Biostatistics
- Safety and medical monitoring & reporting
- Trial master file management
- Medical writing: clinical study protocol development, clinical study reporting
- Functional outsourcing

Polaris Strategic Partners is your partner for better trials. We focus on your needs and operate in a culturally sensitive way. We provide insightful guidance, practical know-how, valuable connections and comprehensive solutions to support you to achieve trial success in the US.

AAVnerGene

AAVnerGene Inc. is an innovative company developing new technologies to make AAV based gene therapy more accessible and affordable. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening platform has high complexity to find the best AAV for each specific disease therapy, so to increase productivity, efficiency and specificity while decrease manufacture pressure, side effects, immunity and price.

With more than 16 years of AAV gene therapy front line expertise, AAVnerGene provides you cutting edge ideas, designs, high quality AAV packaging, products, library construction and screening services. Collaboration is welcome to promote the advance of the thriving area and bring hopes to patients. Together, we find the cures. Please refer to www.AAVnerGene.com for more information and send your questions to daozhan.yu@aavnergene.com.

希麦迪医药
CR Medicon
A PHARMARON Company

An Integrated Clinical Development Platform

CR Medicon is a clinical development CRO dedicated to providing high-quality services including regulatory affairs, medical affairs, clinical operation, data management, statistical analysis, programming, pharmacovigilance and biological sample analysis. CR Medicon is one of the most trusted and fastest-growing clinical trial service providers for domestic and overseas sponsors.

charle.li@crmedicon.com; 732.624.9052; 200 Centennial Ave., Piscataway, NJ 08854

THANK YOU
TO OUR EXECUTIVE COACH & SAPA-DC VOLUNTEERS

Ines Lebow
CEO & Founder
Enterprise Transformation Solutions, LLC

Ines is known as a catalyst for business, having been recruited by multiple companies to transform their sales and business operations. In 2016, Ines launched Enterprise Transformation Solutions, LLC (ETS), a change management consulting firm working with companies seeking a competitive advantage, those looking for a turnaround, and start-ups/scale-ups. She has managed 11 M&A transactions, $800M in revenue implementation, new entity start-ups, and IPO due diligence. Ines holds 3 degrees from American University.

LONG CHEN, MD, PhD

RONG CHEN, MBA

LI FENG, PhD, JD

JIA GUO

FENG LIU, PhD

LINDA QIN, MS

CHEN WANG, PhD

SHIYI WANG, MD

JASON YE

XIAOZHEN "SHAWN" YU, PhD, JD

THANK YOU TO OUR PARTNERS & SPONSORS

Big Idea CONNECTpreneur

BIOCENTURY

BioHealth Innovation

CHINABIO®

Deloitte.

漢康資本 HANKANG CAPITAL

Polaris 华美北辰 Partners for Better Trials

AAVnerGene

希麦迪医药 CR Medicon A PHARMARON Company

Hogan Lovells

YUAN MEDIA 源媒体

bioVILLAGE 杭州湾生命科技园

FOLEY FOLEY & LARDNER LLP

ABOUT SAPA-DC

Founded in 1993, the Sino-American Pharmaceutical Professionals Association (SAPA) has become one of the most active and well-recognized Chinese-heritage professional organizations in the United States. SAPA is an independent, volunteer-based, nonprofit and professional organization with over 6,000 members globally. SAPA now spans multiple metropolitan areas throughout the US, including New Jersey (the original site), New England, Greater Philadelphia, Connecticut, California bay area, Mid-West, and the Washington DC/Maryland area, in addition to a chapter in China.

SAPA-DC resides in the Washington DC/Maryland area, which features numerous government agencies and research institutions (FDA, NIH, NIST, HHMI, etc), top-tier universities including Johns Hopkins University, University of Maryland, George Washington University, and Georgetown University, in addition to over 300 leading pharmaceutical/biotech companies such as AstraZeneca, GSK, and Novavax. The DC/Maryland area is especially recognized as the center of global vaccine, cell and gene therapy research and development, as well as a talent pool where the most experienced and innovative biotech/pharmaceutical professionals are gathered. Sitting in this particularly favorable location, SAPA-DC aims to connect local biomedical and pharmaceutical professionals and facilitate the communication between the US and China pharmaceutical industries through a variety of conferences and social events. SAPA-DC strives to be known in our community in the following five areas: Science, Investment, FDA Regulation, Legal Affairs, and Career Development. Current members of SAPA-DC are mostly from local pharmaceutical and biotech companies, research institutions, universities, government agencies, investment/law/consulting firms and many other healthcare-related fields. More than 80% of our registered members have advanced degrees (PhD, MD, JD, MBA, and MS).